[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 137
1. Darvishian F, Stier EA, Soslow RA, Lin O: Immunoreactivity of p16 in anal cytology specimens: histologic correlation. Cancer; 2006 Feb 25;108(1):66-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of p16 in anal cytology specimens: histologic correlation.
  • BACKGROUND: Cytology has been proposed as a potential screening tool in the evaluation of squamous anorectal disease in view of the morphologic similarities between anal and cervical squamous lesions.
  • Due to potential diagnostic pitfalls in anal cytology, p16 overexpression in these specimens was studied.
  • No cell immunoreactive for p16 was found in 15 cases (5 benign cases and 10 cases with either LSIL or HSIL).
  • The sensitivity and specificity of p16 immunoreactivity in the detection of anal intraepithelial neoplasia or carcinoma were 72% and 71%, respectively.
  • CONCLUSIONS: The presence of p16 immunoreactivity is a good predictor of dysplasia in anal specimens.
  • [MeSH-major] Anus Neoplasms / pathology. Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Neoplasms, Squamous Cell / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16404747.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


2. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.
  • Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


3. Cui Y, Koop EA, van Diest PJ, Kandel RA, Rohan TE: Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer. Breast Cancer Res Treat; 2007 Jul;104(1):103-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.
  • Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.
  • We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.
  • The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]
  • [Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]
  • [Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]
  • [Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]
  • [Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]
  • [Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]
  • [Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • (PMID = 17061043.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2092407
  •  go-up   go-down


Advertisement
4. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res; 2008 Jun 1;14(11):3327-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes differentially expressed in benign versus malignant thyroid tumors.
  • PURPOSE: Although fine-needle aspiration biopsy is the most useful diagnostic tool in evaluating a thyroid nodule, preoperative diagnosis of thyroid nodules is frequently imprecise, with up to 30% of fine-needle aspiration biopsy cytology samples reported as "suspicious" or "indeterminate."
  • EXPERIMENTAL DESIGN: In an attempt to identify diagnostic markers for the preoperative distinction of these lesions, we chose to study by microarray analysis the eight different thyroid tumor subtypes that can present a diagnostic challenge to the clinician.
  • RESULTS: Our microarray-based analysis of 94 thyroid tumors identified 75 genes that are differentially expressed between benign and malignant tumor subtypes.
  • Of these, 33 were overexpressed and 42 were underexpressed in malignant compared with benign thyroid tumors.
  • CONCLUSIONS: Our results suggest that these 12 genes could be useful in the development of a panel of markers to differentiate benign from malignant tumors and thus serve as an important first step in solving the clinical problem associated with suspicious thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):56-63 [17943974.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7637-44 [15569996.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1693-9 [15753364.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Apr;27(2):101-10 [15913203.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):91-7 [15713121.001]
  • [Cites] Methods Mol Med. 2005;103:89-101 [15542899.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1069-83 [16050784.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]
  • [Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4773-83 [16899629.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 [10641790.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] Thyroid. 2001 Mar;11(3):271-7 [11327619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]
  • [Cites] Cell Calcium. 2002 Jul;32(1):1-10 [12127057.001]
  • [Cites] J Comput Biol. 2002;9(3):505-11 [12162889.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5351-7 [12235006.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7077-91 [12370830.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] J Pathol. 2003 Feb;199(2):176-84 [12533830.001]
  • [Cites] Pathol Oncol Res. 2002;8(4):231-40 [12579208.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1710-20 [12738725.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1191-8 [12807722.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):667-74; discussion 675-6 [15383794.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):311-9 [9164872.001]
  • [Cites] Br J Cancer. 1997;75(9):1279-83 [9155046.001]
  • [Cites] Genomics. 1998 Mar 15;48(3):377-80 [9545645.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528 [16931590.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:12-7 [17091451.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:18-25 [17091452.001]
  • [Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):1935-42 [17161346.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4193-8 [9751634.001]
  • (PMID = 18519760.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247-05; United States / NCI NIH HHS / CA / CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247; United States / NCI NIH HHS / CA / R01-CA107247-01A1; United States / NCI NIH HHS / CA / CA107247-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS282977; NLM/ PMC3086681
  •  go-up   go-down


5. Bernard JE, Butler MO, Sandweiss L, Weidner N: Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol; 2008 May;16(3):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.
  • Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.
  • To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.
  • One hundred thirty-three consecutive anal tissue specimens, from 128 patients were studied.
  • One hundred and eight were anal biopsies and 25 were hemorrhoidectomy specimens.
  • We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV
  •  go-up   go-down


6. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of anal canal: a case report.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Examination revealed a 4 cm friable mass attached to the anus by a stalk.
  • The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.
  • We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


7. Bereman MS, Williams TI, Muddiman DC: Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem; 2009 Feb 1;81(3):1130-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
  • In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).
  • However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Female. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Hydrophobic and Hydrophilic Interactions. Lectins / blood. Lectins / chemistry. Male. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]
  • [Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]
  • [Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]
  • [Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]
  • [Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]
  • [Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]
  • [Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]
  • [Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]
  • [Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]
  • [Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]
  • [Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]
  • [Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]
  • [Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]
  • [Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]
  • (PMID = 19113831.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471
  •  go-up   go-down


8. Bhattacharjee N, Li N, Keenan TM, Folch A: A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors. Integr Biol (Camb); 2010 Nov;2(11-12):669-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors.
  • In this paper, we describe axonal responses of mouse cortical neurons in a "neuron-benign" gradient-generator device based on an open chamber that can establish highly stable gradients of diffusible molecules for at least 6 h with negligible shear stress, and also allows the neurons to thrive for at least 2 weeks.
  • [MeSH-minor] Animals. Axons / drug effects. Axons / physiology. Cell Culture Techniques. Cell Tracking. Equipment Design. Female. Mice. Nerve Growth Factors / pharmacology. Neurogenesis. Pregnancy. Signal Transduction. Tumor Suppressor Proteins / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 1996 Aug;17(2):203-15 [8780645.001]
  • [Cites] J Neurosci Res. 1995 Dec;42(5):674-83 [8600300.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Mol Cell Neurosci. 1997;8(6):417-29 [9143559.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):275-9 [9230436.001]
  • [Cites] Neuron. 1997 Sep;19(3):575-89 [9331350.001]
  • [Cites] Neuron. 1997 Dec;19(6):1211-24 [9427245.001]
  • [Cites] Development. 1997 Dec;124(24):5063-74 [9362464.001]
  • [Cites] Cell. 1999 Jun 25;97(7):821-4 [10399909.001]
  • [Cites] Curr Opin Neurobiol. 1999 Oct;9(5):603-15 [10508749.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):833-9 [15679351.001]
  • [Cites] Lab Chip. 2005 Apr;5(4):401-6 [15791337.001]
  • [Cites] Lab Chip. 2005 Jun;5(6):611-8 [15915253.001]
  • [Cites] Exp Cell Res. 2005 Dec 10;311(2):307-16 [16263111.001]
  • [Cites] Nat Neurosci. 2006 Apr;9(4):511-8 [16520734.001]
  • [Cites] Dev Biol. 2006 Apr 1;292(1):13-24 [16476423.001]
  • [Cites] Biomed Microdevices. 2006 Jun;8(2):109-18 [16688570.001]
  • [Cites] Development. 2006 Jul;133(13):2487-95 [16763203.001]
  • [Cites] Lab Chip. 2007 Jun;7(6):763-9 [17538719.001]
  • [Cites] Langmuir. 2007 Oct 23;23(22):10910-2 [17910490.001]
  • [Cites] Lab Chip. 2008 Jan;8(1):34-57 [18094760.001]
  • [Cites] Lab Chip. 2008 Feb;8(2):227-37 [18231660.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):698-706 [18469807.001]
  • [Cites] Lab Chip. 2008 Aug;8(8):1292-9 [18651071.001]
  • [Cites] Lab Chip. 2008 Sep;8(9):1468-77 [18818801.001]
  • [Cites] Lab Chip. 2008 Sep;8(9):1507-15 [18818806.001]
  • [Cites] Lab Chip. 2010 Jan 7;10(1):116-22 [20024059.001]
  • [Cites] Cell. 2010 May 14;141(4):632-44 [20434207.001]
  • [Cites] J Comp Neurol. 2000 Jan 10;416(2):201-12 [10581466.001]
  • [Cites] Int J Dev Neurosci. 2000 Nov;18(7):643-51 [10978842.001]
  • [Cites] Nat Neurosci. 2001 Nov;4 Suppl:1169-76 [11687826.001]
  • [Cites] Neuron. 2001 Nov 20;32(4):605-17 [11719202.001]
  • [Cites] Prog Neurobiol. 2001 Dec;65(6):593-608 [11728645.001]
  • [Cites] J Neurobiol. 2002 Apr;51(1):9-23 [11920724.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]
  • [Cites] Nat Biotechnol. 2002 Aug;20(8):826-30 [12091913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12542-7 [12237407.001]
  • [Cites] Lab Chip. 2004 Oct;4(5):420-4 [15472724.001]
  • [Cites] Nature. 1988 Dec 22-29;336(6201):775-8 [3205306.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • (PMID = 20957287.001).
  • [ISSN] 1757-9708
  • [Journal-full-title] Integrative biology : quantitative biosciences from nano to macro
  • [ISO-abbreviation] Integr Biol (Camb)
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064387
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1
  • [Other-IDs] NLM/ NIHMS513943; NLM/ PMC3786697
  •  go-up   go-down


9. Chen SP, Wang XP: Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation. Chin J Integr Med; 2006 Sep;12(3):221-3
Hazardous Substances Data Bank. GLYCERIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation.
  • OBJECTIVE: To study the effect of Simotang oral liquid and glycerin enema on the patients' bowel sound (BS) restoration and anal exhaust after abdominal gynecological operation.
  • METHOD: Ninety patients with benign tumor who had undergone gynecological operation were randomly divided into the Simotang group, treated after operation with Simotang oral liquid; the enema group, treated with glycerin enema, and the control group, non-treated.
  • The restoration time of BS and anal exhaust were observed.
  • RESULTS: Compared with the control group, the restoration time of BS and anus exhaust were both significantly shorter in the Simotang group and the enema group, showing statistical significance (P < 0.05); but the difference between the two treated groups was insignificant (P > 0.05).
  • CONCLUSION: Simotang oral liquid and glycerine enema both could benefit the restoration of anal exhaust and BS after abdominal operation.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005087.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; PDC6A3C0OX / Glycerol
  •  go-up   go-down


10. Krishna CM, Sockalingum GD, Bhat RA, Venteo L, Kushtagi P, Pluot M, Manfait M: FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues. Anal Bioanal Chem; 2007 Mar;387(5):1649-56
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues.
  • FTIR and Raman spectroscopic studies of formalin-fixed normal, benign, and malignant ovarian tissues have been undertaken in order to investigate and attempt to understand the underlying biochemical changes associated with the disease, and to explore the feasibility of discriminating between these different tissue types.
  • Among the pathological tissues studied, spectra from benign tissues seem to contain more proteins and less DNA and lipids compared to malignant tissue spectra.
  • FTIR and Raman spectra of both normal and benign tissues showed more similarities than those of malignant tissues.
  • Cluster analysis of first-derivative Raman spectra in the 700-1700 cm(-1) range gave two clear groups, one corresponding to malignant and the other to normal+benign tissues.
  • At a lower heterogeneity level, the normal+benign cluster gave three nonoverlapping subclusters, one corresponding to normal and two for benign tissues.
  • Cluster analysis of second-derivative FTIR spectra in the combined spectral regions of 1540-1680 and 1720-1780 cm(-1) resulted into two clear clusters corresponding to malignant and normal+benign tissues.
  • The cluster corresponding to normal+benign tissues produced nonoverlapping subclusters for normal and benign tissues at a lower heterogeneity level.
  • The findings of this study demonstrate the feasibility of Raman and FTIR microspectroscopic discrimination of formalin-fixed normal, benign, and malignant ovarian tissues.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Spectroscopy, Fourier Transform Infrared / methods. Spectrum Analysis, Raman / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043798.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fixatives; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


11. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, Valentini V, Trodella L, Caricato M, Coppola R: Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology; 2005 May-Jun;52(63):780-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?
  • We report the case of a 47-year-old HIV-negative male affected by a perianal ulcer which occurred after chemoradiation delivered for anal cancer.
  • Uncontrollable pain and anal stenosis were also present; abdominoperineal resection with a large excision of perianal tissues and reconstruction with bilateral musculocutaneous gracilis flaps was therefore performed.
  • Histology did not confirm tumor recurrence.
  • The introduction of radiotherapy and concomitant chemotherapy has revolutionized the treatment of anal cancer, avoiding demolitive surgery in a large subset of patients.
  • Radionecrosis is an uncommon but potentially devastating event occurring in up to 10% of patients undergoing radiotherapy for anal cancer.
  • It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems (recurrence vs. benign post-attinic lesion).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Perineum / radiation effects. Radiodermatitis / diagnosis. Ulcer / diagnosis
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Surgical Flaps

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966204.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Herrera Espiñeira C, Fernández Valdivia J, López-Cuervo JE, Martínez Tapias J: Textural analysis in the diagnosis of benign and malignant breast cells. Anal Quant Cytol Histol; 2007 Dec;29(6):365-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Textural analysis in the diagnosis of benign and malignant breast cells.
  • OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.
  • The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.
  • RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.
  • Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225392.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Rehnberg J, Zendehrokh N, Dejmek A: Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions. Anal Quant Cytol Histol; 2007 Aug;29(4):217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
  • OBJECTIVE: To determine the proliferation rates of mesothelial cells in metastatic and benign effusions.
  • STUDY DESIGN: Immunohistochemistry was performed on formalin-fixed pellets from 16 malignant and 9 benign clinical effusions.
  • Dual staining with antibodies against Ki-67 (MIB-1) and desmin was applied to all effusions to differentiate between benign mesothelial cells and malignant cells, and the proportions of desmin+/Ki-67+ and desmin+/Ki-67- cells were calculated.
  • RESULTS: In 7 malignant effusions no proliferating mesothelial cells were found, whereas some rate of proliferation could always be demonstrated in mesothelial cells in the benign effusions.
  • Further, the median proportions of proliferating cells, malignant 2% vs. benign 11%, differed significantly.
  • CONCLUSIONS: To our knowledge this finding has not been previously described, and it may have implications for both cytologic diagnosis and the understanding of tumor biology and the interaction between tumor cells and mesothelial cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879629.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Ki-67 Antigen
  •  go-up   go-down


14. Reschner A, Harlin H, Laven B, Eriksson F, Pisa P, Egevad L: Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol; 2009 Apr;31(2):74-82
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
  • OBJECTIVE: To investigate the expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
  • STUDY DESIGN: We investigated by quantitative real-time polymerase chain reaction the expression of indoleamine 2,3-dioxygenase, arginase 1, arginase 2, inducible form of nitric oxide synthase, cyclooxygenase 2 (COX-2), programmed death ligand 1 and interleukin 10 in 36 matched pairs of samples from prostate cancer and benign prostatic tissue.
  • RESULTS: Among the genes analyzed, arginase 2 and COX-2 showed statistically significant up-regulation and down-regulation, respectively, in malignant compared to benign prostate tissue.
  • In addition, arginase 1 was more often present in cancer than benign samples.
  • We provide a snapshot of immunosuppressive gene expression at the transcriptional level in the prostate tumor microenvironment.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402383.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / IL10 protein, human; 0 / Immunologic Factors; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 130068-27-8 / Interleukin-10; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


15. Voss M, Trojan L, Steidler A, Weiss C, Grobholz R, Alken P, Michel MS: Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia. Anal Quant Cytol Histol; 2008 Aug;30(4):199-202
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
  • OBJECTIVE: To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.
  • There was no correlation of VEGF-C to tumor stage, grading or the preoperative prostate-specific antigen values.
  • CONCLUSION: We cannot recommend VEGF-C serum level as a marker for tumor growth in PCa.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773737.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


16. Wells WA, Wang X, Daghlian CP, Paulsen KD, Pogue BW: Phase contrast microscopy analysis of breast tissue: differences in benign vs. malignant epithelium and stroma. Anal Quant Cytol Histol; 2009 Aug;31(4):197-207
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase contrast microscopy analysis of breast tissue: differences in benign vs. malignant epithelium and stroma.
  • OBJECTIVE: To assess how optical scatter properties in breast tissue, as measured by phase contrast microscopy and interpreted pathophysiologically, might be exploited as a diagnostic tool to differentiate cancer from benign tissue.
  • STUDY DESIGN: We evaluated frozen human breast tissue sections of adipose tissue, normal breast parenchyma, benign fibroadenoma tumors and noninvasive and invasive malignant cancers by phase contrast microscopy through quantification of grayscale values, using multiple regions of interest (ROI).
  • RESULTS: Stroma demonstrated significantly higher scatter intensity than did epithelium, with lower scattering in tumor-associated stroma as compared with normal or benign-associated stroma.
  • Measures were comparable for invasive and noninvasive malignant tumors but were higher than those found in benign tumors and were lowest in adipose tissue.
  • CONCLUSION: Significant differences were found in scatter coefficient properties of epithelium and stroma across diagnostic categories of breast tissue, particularly between benign and malignant-associated stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] Biophys J. 2002 Apr;82(4):2256-64 [11916880.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):53-60 [12672030.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3556-9 [12839941.001]
  • [Cites] Radiology. 2004 May;231(2):571-80 [15128998.001]
  • [Cites] Anal Quant Cytol Histol. 2004 Jun;26(3):166-74 [15218693.001]
  • [Cites] Phys Med Biol. 2004 Aug 21;49(16):3573-83 [15446788.001]
  • [Cites] Pathol Res Pract. 1984 Sep;179(1):61-6 [6504769.001]
  • [Cites] Surg Gynecol Obstet. 1987 Dec;165(6):523-9 [2825366.001]
  • [Cites] J Dermatol Surg Oncol. 1993 Sep;19(9):869-74 [7690052.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2497-503 [10811131.001]
  • [Cites] Radiology. 2000 Mar;214(3):895-901 [10715065.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1267-71 [7573688.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Opt Lett. 2007 Apr 15;32(8):933-5 [17375158.001]
  • [Cites] J Surg Oncol. 1997 Dec;66(4):248-53 [9425328.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):220-6 [9607622.001]
  • [Cites] Phys Med Biol. 1998 Sep;43(9):2555-67 [9755945.001]
  • [Cites] Phys Med Biol. 1998 Oct;43(10):2845-52 [9814522.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1122-8 [15568931.001]
  • [Cites] Biophys J. 2005 Apr;88(4):2929-38 [15653724.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]
  • [Cites] Opt Lett. 2005 Jun 1;30(11):1354-6 [15981531.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064007 [17212530.001]
  • [Cites] Histopathology. 2007 Feb;50(3):338-47 [17257129.001]
  • (PMID = 19736867.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA105480-010002; United States / NCI NIH HHS / CA / U54 CA105480; None / None / / U54 CA105480-010002; United States / NCI NIH HHS / CA / CA080139-09; United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P01 CA080139-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS183687; NLM/ PMC2857332
  •  go-up   go-down


17. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


18. Karanikolas BD, Figueiredo ML, Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res; 2009 Sep;7(9):1456-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
  • Although this correlation means EZH2 could prove valuable as a biomarker in clinical settings, the question remains whether EZH2 is actually responsible for the initiation of these more aggressive tumor types.
  • In this study, EZH2-mediated neoplastic transformation of the normal prostate epithelial cell line benign prostate hyperplasia 1 (BPH1) was confirmed by in vivo tumor growth and in vitro colony formation.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 1999 Oct;18(5):455-67 [10601733.001]
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8143-9 [11719443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5 [11880635.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1981-9 [12702592.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):155-64 [15196462.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5759-69 [15208672.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]
  • [Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]
  • [Cites] J Virol. 1998 Oct;72(10):8150-7 [9733856.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Exp Gerontol. 1999 Apr;34(2):275-87 [10363793.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):117-25 [15699631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6269-80 [16007202.001]
  • [Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]
  • [Cites] Methods Enzymol. 2006;407:660-76 [16757360.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24790-802 [16766534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):466-77 [18058808.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] J Cutan Pathol. 2007 Aug;34(8):597-600 [17640228.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):255-63 [18095286.001]
  • [Cites] Dis Markers. 2008;24(3):157-65 [18334737.001]
  • (PMID = 19723877.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131-08; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / CA101904-07
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS159142; NLM/ PMC2794652
  •  go-up   go-down


19. Ye C, Shu XO, Wen W, Pierce L, Courtney R, Gao YT, Zheng W, Cai Q: Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases. Breast Cancer Res Treat; 2008 Apr;108(3):427-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.
  • In this study, we developed a quantitative real-time PCR assay to assess the level of the DeltamtDNA(4977) mutation in tumor tissue samples from 55 primary breast cancer patients and 21 patients with benign breast disease (BBD).
  • The DeltamtDNA(4977) mutation levels were lower in tumor tissues than in adjacent normal tissues in both breast cancer and BBD subjects.
  • No significant difference between breast cancer and BBD patients was found in the DeltamtDNA(4977) mutation levels of tumor tissues and adjacent normal tissues.
  • The DeltamtDNA(4977) mutation levels were not significantly associated with clinicopathological characteristics (age, histology, tumor stage, and ER/PR status) in breast cancer or BBD patients.

  • Genetic Alliance. consumer health - Mitochondrial Disorders.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):352-5 [10592272.001]
  • [Cites] Ai Zheng. 2004 Nov;23(11):1297-301 [15522177.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):295-300 [10861490.001]
  • [Cites] J Pathol. 2000 Jul;191(3):274-81 [10878549.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):70-6 [10933858.001]
  • [Cites] Mutat Res. 2001 Jun 27;493(1-2):67-74 [11516716.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):158-62 [11752280.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Clin Chim Acta. 2002 Apr;318(1-2):33-40 [11880110.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 15;30(14):e68 [12136116.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7031-41 [12460924.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):985-93 [14871829.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):119-26 [15068836.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1011:154-67 [15126293.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1560-4 [15162525.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):145-52 [15375011.001]
  • [Cites] Genet Mol Res. 2004;3(3):395-409 [15614730.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1270-4 [15477759.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 24;332(1):43-9 [15896297.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):19-28 [15892105.001]
  • [Cites] Int J Neuropsychopharmacol. 2005 Dec;8(4):515-22 [16202181.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:93 [16620376.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2390-6 [15150555.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1753-8 [15274351.001]
  • [Cites] Environ Mol Mutagen. 2004;44(4):313-20 [15476199.001]
  • [Cites] Nature. 1981 Apr 9;290(5806):457-65 [7219534.001]
  • [Cites] Cytogenet Cell Genet. 1995;71(1):99-103 [7606938.001]
  • [Cites] Eur J Biochem. 1998 Oct 1;257(1):192-201 [9799119.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):107-15 [10064854.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):147 [10508508.001]
  • [Cites] Br J Haematol. 1999 Dec;107(4):861-9 [10606895.001]
  • (PMID = 17541740.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA064277; United States / NCI NIH HHS / CA / R01 CA 064277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  • [Other-IDs] NLM/ NIHMS526435; NLM/ PMC3836503
  •  go-up   go-down


20. Garrison JB, Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res; 2006 Jan 1;66(1):464-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.
  • In this study, the molecular events initiating this apoptotic effect were further investigated in vitro using the human androgen-independent prostate cancer cells PC-3 and the human benign prostate epithelial cells BPH-1.
  • These results show that doxazosin exerts its apoptotic effects against benign and malignant prostate cells via a death receptor-mediated mechanism with a potential integrin contribution towards cell survival outcomes.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Cell Death Differ. 2005 Mar;12(3):233-42 [15665818.001]
  • [Cites] Cell Tissue Res. 2000 Jul;301(1):153-62 [10928288.001]
  • [Cites] J Cell Biol. 2001 Feb 5;152(3):633-43 [11157988.001]
  • [Cites] J Urol. 2003 Mar;169(3):1150-6 [12576871.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):593-600 [12740905.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2795-804 [12743602.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1615-21 [12771931.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):386-93 [12811833.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37632-6 [12876280.001]
  • [Cites] J Med Chem. 2004 Aug 26;47(18):4453-62 [15317457.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Cell. 1995 May 19;81(4):505-12 [7538907.001]
  • [Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Curr Biol. 1996 Oct 1;6(10):1241-3 [8939562.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):783-9 [9182976.001]
  • [Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):521-32 [9352686.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):76-83 [9426061.001]
  • [Cites] Prostate. 1998 Jul 1;36(2):92-101 [9655261.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5870-5 [9865748.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):963-72 [9815772.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):382-90 [9927051.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7987-92 [10075697.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):603-7 [10080945.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5205-11 [10227994.001]
  • [Cites] Cell Death Differ. 1999 May;6(5):394-401 [10381629.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):371-8 [10408840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704 [10411938.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1043-6 [10508619.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1047-9 [10508612.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1852-9 [11313933.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):319-27 [11803475.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):597-602 [11809715.001]
  • [Cites] Prostate. 2002 Apr 1;51(1):42-9 [11920957.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):231-40 [11987151.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):296-300 [12124829.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):45-54 [10696460.001]
  • (PMID = 16397262.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107575; United States / NCI NIH HHS / CA / R01 CA107575-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adrenergic alpha-Antagonists; 0 / Antigens, CD95; 0 / FADD protein, human; 0 / Fas-Associated Death Domain Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  • [Other-IDs] NLM/ NIHMS19062; NLM/ PMC1850148
  •  go-up   go-down


21. Singh SS, Kim D, Mohler JL: Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. Biomed Eng Online; 2005 May 11;4:31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia.
  • The expression of AR in paired specimens of benign prostate and prostate cancer from 20 African and 20 Caucasian Americans was compared to demonstrate an application of this system.
  • RESULTS: The percent positive nuclei and percent nuclear area were similar by race in both benign prostate hyperplasia and prostate cancer.
  • Intensity of AR immunostaining was similar between races in benign prostate.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IEEE Trans Inf Technol Biomed. 1997 Jun;1(2):128-40 [11020815.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cytometry. 1999 Jan 1;35(1):2-10 [10554175.001]
  • [Cites] J Cell Biochem Suppl. 2000;Suppl 35:151-7 [11389545.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):219-26 [11786415.001]
  • [Cites] Curr Urol Rep. 2002 Feb;3(1):67-74 [12084222.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):20-4 [12559071.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] Cytometry A. 2003 Sep;55(1):30-42 [12938186.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):146-50 [14747438.001]
  • [Cites] Prostate. 2004 Jun 1;59(4):460-8 [15065095.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):75-9 [15158050.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):928-34 [15223964.001]
  • [Cites] Anal Quant Cytol Histol. 2004 Aug;26(4):194-200 [15457671.001]
  • [Cites] Cancer. 1980 Apr 15;45(7 Suppl):1929-36 [7370944.001]
  • [Cites] Prostate. 1982;3(4):321-32 [7122329.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):511-9 [1728382.001]
  • [Cites] Urol Res. 1991;19(6):333-6 [1722053.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2574-80 [7680949.001]
  • [Cites] J Urol. 1993 May;149(5):1015-9 [7683339.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4096-102 [7518349.001]
  • [Cites] J Urol. 1998 Mar;159(3):641-9 [9474117.001]
  • [Cites] Comput Methods Programs Biomed. 2000 Aug;63(1):55-70 [10927155.001]
  • [Cites] Annu Rev Biochem. 1994;63:451-86 [7979245.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Dec;16(6):400-14 [7536003.001]
  • (PMID = 15888205.001).
  • [ISSN] 1475-925X
  • [Journal-full-title] Biomedical engineering online
  • [ISO-abbreviation] Biomed Eng Online
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC1145186
  •  go-up   go-down


22. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT: Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal; 2007;21(3):193-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
  • As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.
  • Both of these benign tumors are known to be at risk of developing into cancer.
  • During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.
  • In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.
  • It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood


23. Nattkemper TW, Wismüller A: Tumor feature visualization with unsupervised learning. Med Image Anal; 2005 Aug;9(4):344-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor feature visualization with unsupervised learning.
  • Dynamic contrast enhanced magnetic resonance imaging (DCE MRI) is applied for diagnosis and therapy control of breast cancer.
  • Computer-based diagnosis (CAD) systems have been proposed to analyze and classify signal time curve data, extracted from hand selected ROI in the DCE MRI data.
  • In this paper, we apply the self-organizing map (SOM) to a set of time curve feature vectors of single voxels from seven benign lesions and seven malignant tumors.
  • Using the trained SOM, we are able to identify voxels with benign or malignant signal characteristics and to visualize lesion cross-sections with pseudo-colors.
  • [MeSH-minor] Contrast Media. Diagnosis, Computer-Assisted. Female. Gadolinium DTPA. Humans


24. Versa-Ostojić D, Stanković T, Stemberger-Papić S, Vrdoljak-Mozetic D, Manestar M, Krasević M: Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints. Anal Quant Cytol Histol; 2008 Jun;30(3):160-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
  • OBJECTIVE: To determine the morphometric characteristics of nuclei and silver-stained nucleolar organizer regions (AgNORs) on cytologic imprints and their value in differential cytodiagnosis of benign, atypical proliferative (borderline) and malignant ovarian mucinous tumors.
  • STUDY DESIGN: Forty-six mucinous ovarian tumor imprints (16 benign, 15 borderline, 15 malignant), were analyzed.
  • The nuclear area in benign tumors was larger than that in borderline tumors; malignant tumors had the highest values.
  • The total AgNOR area, number and relative area increased from benign through malignant tumors, with statistically significant differences among all groups.
  • By AgNOR size distribution, small AgNORs discriminate malignant from borderline and benign tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630841.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


25. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA: Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene; 2008 Nov 27;27(56):7118-30
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
  • In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months.
  • Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n=140, P-value <0.0001).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jan 1;67(1):75-84 [17210685.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2467-75 [17690110.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):1-10 [10696454.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):230-5 [10861498.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2314-29 [10995388.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] J Cell Physiol. 2001 Feb;186(2):153-68 [11169452.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]
  • [Cites] J Cell Biochem. 2002;86(4):665-77 [12210733.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1345-56 [15316903.001]
  • [Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]
  • [Cites] J Urol. 1982 Oct;128(4):858-61 [7143620.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Nature. 1984 Jan 12-18;307(5947):131-6 [6318122.001]
  • [Cites] Endocrinology. 1990 Mar;126(3):1343-54 [2307108.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):722-30 [2384450.001]
  • [Cites] Cell. 1991 Jan 25;64(2):231 [1846319.001]
  • [Cites] Acta Anat (Basel). 1992;143(2):139-50 [1598820.001]
  • [Cites] J Cell Sci. 1992 Jun;102 ( Pt 2):361-72 [1400638.001]
  • [Cites] Cancer. 1994 Aug 1;74(3 Suppl):1030-44 [8039137.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1499-503 [7614683.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5408-14 [7585610.001]
  • [Cites] J Histochem Cytochem. 1998 Mar;46(3):379-88 [9487120.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2520-3 [9635571.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1625-30 [9676836.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1255-61 [9816295.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5329-32 [9850059.001]
  • [Cites] Genes Cells. 1998 Oct;3(10):659-70 [9893023.001]
  • [Cites] Mol Cancer. 2007;6:69 [17967179.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2773-84 [16407846.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):22-32 [16023783.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Rev Endocr Metab Disord. 2006 Jun;7(1-2):41-9 [16944325.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] Growth Factors. 1998;16(2):101-10 [9932228.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1366-71 [10096572.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • (PMID = 18724388.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108646; United States / NIGMS NIH HHS / GM / F31 GM079879; United States / PHS HHS / / FGM079879A; United States / NCI NIH HHS / CA / U54 CA126505; United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / R01 CA108646-04; United States / NCI NIH HHS / CA / T32 CA009592; United States / NCI NIH HHS / CA / R01 CA108646; None / None / / R01 CA108646-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ NIHMS142310; NLM/ PMC3222150
  •  go-up   go-down


26. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol; 2009 Oct;115(1):112-20
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
  • OBJECTIVE: Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis.
  • Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.
  • Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines.
  • Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).
  • Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.
  • CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.
  • The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.
  • Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]
  • [Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]
  • [Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]
  • (PMID = 19647308.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307
  •  go-up   go-down


27. Walts AE, Lechago J, Bose S: P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia. Am J Surg Pathol; 2006 Jul;30(7):795-801
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.
  • P16 is a tumor suppressor gene product, shown to be overexpressed in most cervical carcinomas and dysplasias associated with high-risk human papilloma virus (HPV) infection.
  • HPV is also associated with anal squamous dysplasias and carcinomas.
  • Significant interobserver and intraobserver variation exists in the interpretation of biopsies for anal intraepithelial neoplasia (AIN).
  • This study was undertaken to assess the potential role of p16 and Ki67 immunohistochemical expression in refining the diagnosis and grading of AIN.One-hundred and four anal biopsies from 74 patients were retrieved from the surgical pathology files of the department.
  • Conversely, absence of a p16 band of positivity coupled with Ki67 positivity in <50% of nuclei was frequently associated with benign lesions.
  • We conclude that when used together and evaluated in conjunction with H&E stained sections, p16 and Ki67 immunoexpression is a useful adjunct in the diagnosis and grading of AIN.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ki-67 Antigen / metabolism. Papillomavirus Infections / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. DNA, Viral / analysis. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Papillomaviridae / genetics. Papillomaviridae / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819320.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Ki-67 Antigen
  •  go-up   go-down


28. Yegingil H, Shih WY, Shih WH: Probing model tumor interfacial properties using piezoelectric cantilevers. Rev Sci Instrum; 2010 Sep;81(9):095104
Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing model tumor interfacial properties using piezoelectric cantilevers.
  • Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth.
  • It is of interest to characterize tumor branchiness (roughness) to differentiate invasive malignant breast cancer from noninvasive ones.
  • In this study, we examined the shear modulus (G) to elastic modulus (E) ratio, G/E, as a quantity to describe model tumor interfacial roughness using a piezoelectric cantilever capable of measuring both tissue elastic modulus and tissue shear modulus.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]
  • [Cites] Arch Surg. 2001 Feb;136(2):204-8 [11177142.001]
  • [Cites] J Digit Imaging. 2002;15 Suppl 1:224-7 [12105735.001]
  • [Cites] Ultrasound Med Biol. 2003 Jun;29(6):813-23 [12837497.001]
  • [Cites] Annu Rev Biomed Eng. 2003;5:57-78 [12704084.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):111-21 [14719692.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] Phys Med Biol. 2006 Jan 21;51(2):425-41 [16394348.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):215-28 [15798297.001]
  • [Cites] Phys Med Biol. 2007 Mar 21;52(6):1565-76 [17327649.001]
  • [Cites] Med Eng Phys. 2008 Oct;30(8):1013-9 [18495518.001]
  • [Cites] Rev Sci Instrum. 2007 Nov;78(11):115101 [18052498.001]
  • [Cites] Med Image Anal. 2007 Aug;11(4):361-73 [17509927.001]
  • (PMID = 20887005.001).
  • [ISSN] 1089-7623
  • [Journal-full-title] The Review of scientific instruments
  • [ISO-abbreviation] Rev Sci Instrum
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000720; United States / NIBIB NIH HHS / EB / 1 R01 EB000720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 12626-81-2 / lead titanate zirconate; 1302-87-0 / clay; 2P299V784P / Lead; C6V6S92N3C / Zirconium; D1JT611TNE / Titanium
  • [Other-IDs] NLM/ PMC2955722
  •  go-up   go-down


29. Seman M, Bretagnol F, Guedj N, Maggiori L, Ferron M, Panis Y: Transanal endoscopic microsurgery (TEM) for rectal tumor: the first French single-center experience. Gastroenterol Clin Biol; 2010 Sep;34(8-9):488-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery (TEM) for rectal tumor: the first French single-center experience.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) allows complete local excision of rectal tumor, especially in the middle and upper part of the rectum, and provides an alternative to conventional surgery.
  • This is a report of the first French single-center experience to assess the feasibility and postoperative results for rectal tumor excised by TEM.
  • The median distance from the anal verge was 60mm (range: 10-140).
  • CONCLUSION: TEM is a safe and effective procedure with low morbidity for local rectal tumor resection.
  • It allows local excision of benign tumors, especially those that are inaccessible to conventional local surgery resection, thereby avoiding radical surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20621428.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


30. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res; 2007 Nov 1;67(21):10564-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.
  • Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors.
  • Pituitary tumor-transforming gene (Pttg) deletion results in pituitary hypoplasia, low pituitary cell proliferation rates, and rescue of pituitary tumor development in Rb(+/-) mice.
  • As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Pttg(-/-)p21(-/-) relative to Rb(+/-)Pttg(-/-) pituitary glands, p21-dependent senescence provoked by Pttg deletion may underlie pituitary hypoplasia and decreased tumor development in Rb(+/-)Pttg(-/-) mice.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):125-6 [9744268.001]
  • [Cites] EMBO J. 1999 Jan 4;18(1):22-7 [9878046.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Mech Dev. 1999 Mar;81(1-2):23-35 [10330482.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7011-9 [10490638.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51100-6 [15456744.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):25-36 [17189716.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):748-53 [11698192.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Nat Cell Biol. 2000 Mar;2(3):148-55 [10707085.001]
  • [Cites] Pituitary. 1999 May;1(3-4):169-79 [11081195.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10305-9 [12124396.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Minerva Endocrinol. 2002 Dec;27(4):277-85 [12511850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):25-39, vi [12690977.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2814-21 [12767095.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):1998-2008 [15021887.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3296-307 [15021915.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] J Cell Biol. 1997 Jan 13;136(1):1-4 [9026502.001]
  • (PMID = 17975001.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-09; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979; United States / NCI NIH HHS / CA / R01 CA075979-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Retinoblastoma Protein; 0 / Securin; 0 / Sp1 Transcription Factor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS121885; NLM/ PMC2770267
  •  go-up   go-down


31. Piura B, Rabinovich A, Sinelnikov I, Delgado B: Tailgut cyst initially misdiagnosed as ovarian tumor. Arch Gynecol Obstet; 2005 Oct;272(4):301-3
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst initially misdiagnosed as ovarian tumor.
  • INTRODUCTION: Tailgut cyst (retrorectal cystic hamartoma) is an uncommon congenital lesion that arises from remnants of the embryonic post-anal gut.
  • It is usually benign and located in the retrorectal/presacral space.
  • The initial diagnosis was neoplasm of the right ovary.
  • Based on these histological findings, the final diagnosis was tailgut cyst.
  • CONCLUSION: Tailgut cyst is an uncommon entity that should be included in the differential diagnosis of retrorectal/presacral mass.
  • [MeSH-major] Cysts / diagnosis. Hamartoma / diagnosis. Peritoneal Neoplasms / diagnosis. Rectal Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Hysterectomy. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041543.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. White KY, Rodemich L, Nyalwidhe JO, Comunale MA, Clements MA, Lance RS, Schellhammer PF, Mehta AS, Semmes OJ, Drake RR: Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res; 2009 Feb;8(2):620-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.
  • With the use of seminal fluid samples representative of normal control, benign prostatic disease and prostate cancers, PAP and PSA were enriched by thiophilic absorption chromatography.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]
  • [Cites] Clin Biochem. 2007 Mar;40(5-6):343-50 [17306785.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 15;849(1-2):115-28 [17049937.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5103-8 [17785564.001]
  • [Cites] Glycobiology. 2008 Jan;18(1):2-8 [17956937.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):367-74 [18047270.001]
  • [Cites] J Virol. 2008 Feb;82(3):1259-70 [18045939.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):645-9 [18245462.001]
  • [Cites] J Mol Biol. 2008 Feb 29;376(4):1021-33 [18187150.001]
  • [Cites] Glycobiology. 2008 May;18(5):353-66 [18256178.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):945-54 [18386289.001]
  • [Cites] Glycobiology. 2000 Feb;10(2):173-6 [10642608.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):211-8 [10639192.001]
  • [Cites] Breast Cancer Res. 2000;2(5):321-3 [11250723.001]
  • [Cites] BJU Int. 2001 Mar;87(5):423-30 [11298030.001]
  • [Cites] Urology. 2001 Apr;57(4):707-11 [11306387.001]
  • [Cites] Biochim Biophys Acta. 2001 Feb 16;1525(1-2):149-60 [11342264.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1488-95 [11391538.001]
  • [Cites] Proteomics. 2001 Jun;1(6):756-62 [11677781.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):145-53 [11813206.001]
  • [Cites] Glycobiology. 2003 Jun;13(6):457-70 [12626390.001]
  • [Cites] J Am Soc Mass Spectrom. 2004 Mar;15(3):413-23 [14998545.001]
  • [Cites] Biochim Biophys Acta. 1985;780(2):119-50 [3890942.001]
  • [Cites] Science. 1987 May 1;236(4801):582-5 [2953071.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):909-16 [2442609.001]
  • [Cites] Clin Chem. 1993 Feb;39(2):181-95 [7679336.001]
  • [Cites] Protein Sci. 1993 Feb;2(2):183-96 [7680267.001]
  • [Cites] JAMA. 1995 Jan 25;273(4):289-94 [7529341.001]
  • [Cites] Prostate. 1995 Oct;27(4):187-97 [7479385.001]
  • [Cites] Anal Biochem. 1996 Sep 5;240(2):210-26 [8811911.001]
  • [Cites] Urology. 1996 Dec;48(6A Suppl):1-3 [8973692.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1997 Aug 1;695(2):439-43 [9300882.001]
  • [Cites] J Int Fed Clin Chem. 1997 Sep;9(3):120-5 [10174623.001]
  • [Cites] J Urol. 1998 Mar;159(3):935-40 [9474187.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2383-5 [17085105.001]
  • (PMID = 19128049.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA085067-09; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / 2U01 CA98028; United States / NCI NIH HHS / CA / U01 CA085067-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Polysaccharides; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS91585; NLM/ PMC2651839
  •  go-up   go-down


33. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


34. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, Sanioglu C, Arvas M: Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol; 2010 Dec 30;21(4):248-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
  • OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.
  • METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.
  • RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.
  • CONCLUSION: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • (PMID = 21278887.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026304
  • [Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker
  •  go-up   go-down


35. Zhang JF, Gao CF, Wang XL, Zheng GB, Li DH: [Screening and expression of tumor markers in colorectal carcinoma]. Zhonghua Wai Ke Za Zhi; 2007 Apr 1;45(7):459-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening and expression of tumor markers in colorectal carcinoma].
  • OBJECTIVE: To screen the tumor markers of colorectal carcinoma and to investigate their expression in preoperative and postoperative serum.
  • METHODS: The distinct proteins in serum were detected in 87 cases of colorectal carcinoma, 68 cases of benign colorectal diseases and 56 healthy people by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
  • Compared with benign colorectal diseases and healthy control, the expression of the two proteins was obviously up-regulated in colorectal carcinoma (P < 0.01).
  • CONCLUSIONS: Two proteins with mass-to-charge ratios of 5955 Da and 5972 Da could be regarded as tumor markers in colorectal carcinoma, the expression may has some regularity.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Mass Screening / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686301.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Huang YL, Jiang YR, Chen DR, Moon WK: Level set contouring for breast tumor in sonography. J Digit Imaging; 2007 Sep;20(3):238-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Level set contouring for breast tumor in sonography.
  • The echogenicity, echotexture, shape, and contour of a lesion are revealed to be effective sonographic features for physicians to identify a tumor as either benign or malignant.
  • First, a sophisticated preprocessing filter reduces the noise, but preserves the shape and contrast of the breast tumor.
  • An adaptive initial contouring method is then performed to obtain an approximate circular contour of the tumor.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomed Tech (Berl). 2002;47 Suppl 1 Pt 2:633-5 [12465259.001]
  • [Cites] Radiology. 2003 Feb;226(2):504-14 [12563146.001]
  • [Cites] Neuroimage. 2004 Mar;21(3):1037-44 [15006671.001]
  • [Cites] Ultrasound Med Biol. 2004 May;30(5):625-32 [15183228.001]
  • [Cites] Med Image Anal. 2004 Sep;8(3):217-31 [15450217.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:559-88 [11701500.001]
  • [Cites] Med Phys. 2001 Aug;28(8):1652-9 [11548934.001]
  • [Cites] Ultrason Imaging. 2000 Oct;22(4):214-36 [11370905.001]
  • [Cites] Semin Ultrasound CT MR. 2000 Aug;21(4):308-16 [11014253.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):109-14 [9423610.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Apr;23(4):447-58 [15084070.001]
  • [Cites] Radiology. 1999 Nov;213(2):407-12 [10551220.001]
  • [Cites] Radiology. 1999 Dec;213(3):889-94 [10580971.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):696-9 [10843366.001]
  • [Cites] Med Phys. 2000 Aug;27(8):1777-88 [10984224.001]
  • [Cites] Ultrasound Obstet Gynecol. 2005 Oct;26(5):558-66 [16086435.001]
  • [Cites] IEEE Trans Image Process. 2005 Jan;14(1):49-62 [15646872.001]
  • (PMID = 17252171.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043893
  •  go-up   go-down


37. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S: p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A; 2008 Nov 11;105(45):17498-503
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21(Cip1) restrains pituitary tumor growth.
  • As commonly encountered, pituitary adenomas are invariably benign.
  • Pituitary tumor transforming gene (Pttg) deletion results in pituitary p21 induction and abrogates tumor development in Rb(+/-)Pttg(-/-) mice. p21 disruption restores attenuated Rb(+/-)Pttg(-/-) pituitary proliferation rates and enables high penetrance of pituitary, but not thyroid, tumor growth in triple mutant animals (88% of Rb(+/-) and 72% of Rb(+/-)Pttg(-/-)p21(-/-) vs. 30% of Rb(+/-)Pttg(-/-) mice developed pituitary tumors, P < 0.001).
  • Intranuclear p21 accumulates in Pttg-null aneuploid GH-secreting cells, and GH(3) rat pituitary tumor cells overexpressing PTTG also exhibited increased levels of mRNA for both p21 (18-fold, P < 0.01) and ATM (9-fold, P < 0.01).
  • Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5338-47 [11103935.001]
  • [Cites] Mod Pathol. 2001 Jan;14(1):20-8 [11211306.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 15;29(6):1300-7 [11238996.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6234-8 [11507077.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):168-70 [14755273.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5293-303 [10498881.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):5013-25 [16030261.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):11-23 [16372018.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53 [16883174.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):220-30 [16932287.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24731-42 [17569660.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cell. 2007 Oct 19;131(2):309-23 [17956732.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22 [11017877.001]
  • (PMID = 18981426.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / Tumor Suppressor Proteins; 0 / pituitary tumor-transforming protein 1, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


38. Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W, Ewend MG: Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol; 2005 Oct;12(10):1232-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel tortuosity and brain tumor malignancy: a blinded study.
  • Characteristic vessel tortuosity abnormalities appear early during tumor development, affect initially healthy vessels, spread beyond the confines of tumor margins, and do not simply mirror tissue perfusion.
  • The ability to detect and quantify tortuosity abnormalities on high-resolution magnetic resonance angiography (MRA) images offers a new approach to the noninvasive diagnosis of malignancy.
  • MATERIALS AND METHODS: The regional vasculature of 34 healthy subjects was compared with the tumor-associated vasculature of 30 brain tumors before surgical resection.
  • The operator performing the analysis was blinded to the diagnosis.
  • Vessels were segmented from an MRA of each subject, a region of interest was defined in each tumor patient and was mapped to all healthy controls, and a statistical analysis of vessel shape measures was then performed over the region of interest.
  • Many difficult cases were included, such as pinpoint, hemorrhagic, and irradiated tumors, as were hypervascular benign tumors.
  • Tumors were identified as benign or malignant on the basis of histological evaluation.
  • RESULTS: A discriminant analysis performed at the study's conclusion successfully classified all but one of the 30 tumors as benign or malignant on the basis of vessel tortuosity.
  • CONCLUSIONS: Quantitative, statistical measures of vessel shape offer a new approach to the diagnosis and staging of disease.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):111-20 [11310918.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • (PMID = 16179200.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219-07; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / EB000219-07
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53777; NLM/ PMC2517122
  •  go-up   go-down


39. Nagy A, Kovacs T, Lóderer Z: Experiences with PPH gun stapled ileo or coloanal anastomoses after ultralow rectal resections and proctocolectomies with J pouch reconstructions. Acta Chir Iugosl; 2006;53(2):61-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On 47 totalcolectomised FAP and UC patients and 9 low rectal benign or clinically T1 or T2N0 rectal tumor resection there was only 5 radiologically proven anastomotic leakadge without serious septic complications.
  • The anal sphincter function after 6 month of the ileoanal anastomosis remained good in 33/39 and acceptable in 6 cases, if the sphincter function was intact praeoperatively.
  • After the ultra low rectal resections all patients kept the normal anal shpincter function.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Ileum / surgery. Proctocolectomy, Restorative. Rectum / surgery. Surgical Stapling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139887.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


40. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, Flemming N, Seemann S, Distler J, Lewin J, Tetzner R, Weickmann S, Wille U, Liloglou T, Raji O, Walshaw M, Fleischhacker M, Witt C, Field JK: SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer; 2010;10:600
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.
  • BACKGROUND: This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with suspected lung cancer by using bronchial fluid aspirated during bronchoscopy.
  • Such a biomarker would be clinically valuable, especially when, following the first bronchoscopy, a final diagnosis cannot be established by histology or cytology.
  • Fresh-frozen and Saccomanno-fixed samples were used to show the tumor marker performance in different sample types of clinical relevance.
  • DNA methylation of SHOX2 allowed to distinguish between malignant and benign lung disease, i.e. abscesses, infections, obstructive lung diseases, sarcoidosis, scleroderma, stenoses, at high specificity (68% sensitivity [95% CI 62-73%], 95% specificity [95% CI 91-97%]).
  • CONCLUSIONS: Hypermethylation of SHOX2 in bronchial aspirates appears to be a clinically useful tumor marker for identifying subjects with lung carcinoma, especially if histological and cytological findings after bronchoscopy are ambiguous.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bronchi / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / biosynthesis. Homeodomain Proteins / genetics. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1624-8 [11245475.001]
  • [Cites] Methods Mol Biol. 2010;576:155-70 [19882262.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Chest. 2002 May;121(5):1521-6 [12006438.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):777-85 [12360280.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3741-6 [12473584.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):129S-136S [12527572.001]
  • [Cites] Anal Cell Pathol. 2003;25(2):83-8 [12632017.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5525-36 [12934113.001]
  • [Cites] Nucleic Acids Res. 2004;32(1):e10 [14722226.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2284-8 [15073103.001]
  • [Cites] Chest. 2004 Sep;126(3):666-8 [15364737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2406-11 [9482898.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S21-7 [15552778.001]
  • [Cites] Nat Rev Genet. 2005 Aug;6(8):597-610 [16136652.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1633-45 [16273220.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7728-34 [16278393.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):451-69 [16513615.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):181-232 [17137717.001]
  • [Cites] Dis Markers. 2007;23(1-2):73-87 [17325427.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1507-16 [16936776.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):249-55 [17534168.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):549-59 [17481601.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1539-50 [17499000.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] J Thorac Oncol. 2007 Nov;2(11):1044-51 [17975498.001]
  • [Cites] J Pathol. 2007 Dec;213(4):412-9 [17973238.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] BMC Pulm Med. 2008;8:2 [18221551.001]
  • [Cites] Mol Cancer. 2008;7:62 [18616821.001]
  • [Cites] Mol Cancer. 2008;7:81 [18947422.001]
  • [Cites] Clin Sci (Lond). 2009 Jan;116(1):27-35 [19037882.001]
  • [Cites] Adv Cancer Res. 2008;101:93-126 [19055944.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):81-7 [18823011.001]
  • [Cites] Biotechniques. 2009 Sep;47(3):737-44 [19852759.001]
  • [Cites] Thorax. 2002 Jan;57(1):11-4 [11809983.001]
  • (PMID = 21047392.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / SHOX2 protein, human
  • [Other-IDs] NLM/ PMC2988753
  •  go-up   go-down


41. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, Wood D, Johnson T, Shah RB, Meyer C: Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med; 2009 Oct;50(10):1585-93
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Volumes of interest from tumor and benign tissue were defined on the basis of histology and were transferred into coregistered (11)C-choline PET/CT volumes to calculate the mean (T((mean))/B) and maximum (T((max))/B) ratio of tumor to benign prostate background.
  • On the basis of MIB-1/Ki-67 expression in tumor tissues represented on a tissue microarray, we assessed whether (11)C-choline uptake correlated with local Gleason score and tumor proliferation.
  • RESULTS: Histology confirmed 42 tumor nodules with Gleason scores between 3 + 2 and 4 + 4, with volumes ranging from 0.03 to 12.6 cm(3).
  • CONCLUSION: On the basis of our preliminary data using ratios of tumor to benign prostate background, (11)C-choline preferentially identified aggressive primary prostate cancer.
  • [MeSH-major] Choline / chemistry. Positron-Emission Tomography / methods. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Algorithms. Biomarkers, Tumor / metabolism. Carbon Radioisotopes / chemistry. Gene Expression Regulation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prostatectomy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1415-9 [11007527.001]
  • [Cites] Urology. 2000 Nov 1;56(5):721-5 [11068287.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1767-73 [11337374.001]
  • [Cites] Eur Urol. 2002 Jul;42(1):18-23 [12121724.001]
  • [Cites] J Cereb Blood Flow Metab. 2002 Aug;22(8):1019-34 [12172388.001]
  • [Cites] J Urol. 2003 Apr;169(4):1337-40 [12629355.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):9-17 [17828534.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):18-23 [17891394.001]
  • [Cites] Radiology. 2008 Jan;246(1):168-76 [18024440.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1650-9 [18306379.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1065-73 [18200444.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:43S-63S [18523065.001]
  • [Cites] Acad Radiol. 2008 Aug;15(8):1027-39 [18620123.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54 [18695132.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):317-24 [14628097.001]
  • [Cites] Nucl Med Biol. 2004 Oct;31(7):859-65 [15464387.001]
  • [Cites] J Urol. 1997 Feb;157(2):559-62 [8996356.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):842-7 [9189127.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):990-5 [9627331.001]
  • [Cites] Urology. 1998 Oct;52(4):659-62 [9763089.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):195-206 [9873906.001]
  • [Cites] Radiology. 2005 Mar;234(3):804-14 [15734935.001]
  • [Cites] JAMA. 2005 May 4;293(17):2095-101 [15870412.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):668-73 [15765234.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10):1642-9 [16204714.001]
  • [Cites] Curr Med Chem. 2006;13(10):1169-86 [16719778.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):938-44 [16741302.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1249-54 [16883001.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):45-53 [16932935.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4873-8 [17214354.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] Lancet Oncol. 2007 Oct;8(10):855-7 [17913651.001]
  • [Cites] Scand J Urol Nephrol. 2007;41(5):375-81 [17853019.001]
  • [Cites] J Nucl Med. 2000 Sep;41(9):1507-13 [10994730.001]
  • (PMID = 19759109.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / P50 CA069568-10
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carbon Radioisotopes; N91BDP6H0X / Choline
  • [Other-IDs] NLM/ NIHMS170399; NLM/ PMC2837847
  •  go-up   go-down


42. Lexander H, Palmberg C, Auer G, Hellström M, Franzén B, Jörnvall H, Egevad L: Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol; 2005 Oct;27(5):263-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate protein expression in prostate cancer using 2-dimensional gel electrophoresis (2-DE) and mass spectrometry.
  • STUDY DESIGN: Cells were collected from 29 peripheral zone tumors and from benign tissue by scraping cut surfaces of radical prostatectomy specimens.
  • Samples were suspended in a medium with protease inhibitors and prepared for 2-DE.
  • Gels were analyzed, and protein spots that differed quantitatively between tumor and benign tissue were identified via mass spectrometric fingerprinting of tryptic fragments and tandem mass spectrometry sequence analysis.
  • RESULTS: In total, 63 spots differed between cancer and benign samples (p < 0.01); 56 were overexpressed (> 1.5 fold) in cancer and 7 underexpressed (< 0.6 fold).
  • CONCLUSION: The protein profile of prostate cancer differs from that of benign tissue.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447818.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Fatela-Cantillo D, Fernández-Suárez A, Menéndez V, Galán JA, Filella X: Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. J Clin Lab Anal; 2005;19(4):167-71
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients.
  • We evaluated serum levels of soluble fragments of cytokeratin 19 (CYFRA 21-1) by immunoassay (ES-700; Roche Diagnostics, Mannheim, Germany) to assess its usefulness in the diagnosis and follow-up of bladder cancer.
  • The study included 39 patients with a diagnosis of transitional cell carcinoma (group 1) and 190 patients (group 2) with no evidence of tumor.
  • In group 2, 180 patients had a history of bladder cancer, and 10 had benign prostatic hyperplasia.
  • However, CYFRA 21-1 levels did not significantly differ between the patients with benign prostatic hyperplasia and those with bladder cancer (P=0.274).
  • [MeSH-major] Antigens, Neoplasm / blood. Keratins / blood. Urinary Bladder Neoplasms / blood. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Humans. Keratin-19. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025482.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


44. Liu J, Lau SK, Varma VA, Kairdolf BA, Nie S: Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots. Anal Chem; 2010 Jul 15;82(14):6237-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots.
  • Here, we report the use of multiplexed QDs and wavelength-resolved imaging to detect and characterize a class of low-abundant tumor cells in Hodgkin's lymphoma.
  • Known as the Hodgkin's and Reed-Sternberg (HRS) cells, this class of malignant cells is a pathological hallmark in clinical diagnosis, but it comprises only about 1% of the heterogeneous infiltrating cells in lymph node tissues.
  • The results indicate that a distinct QD staining pattern (CD15 positive, CD30 positive, CD45 negative, and Pax5 positive) can be used to not only detect Hodgkin's lymphoma but also differentiate it from benign lymphoid hyperplasia.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] ACS Nano. 2010 May 25;4(5):2755-65 [20377268.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):162-76 [11896065.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Cancer Detect Prev. 2002;26(4):249-55 [12430629.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117 Suppl:S76-94 [14569804.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] J Clin Pathol. 1987 Nov;40(11):1298-304 [3320093.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2905-17 [8639911.001]
  • [Cites] J Pathol. 1997 Apr;181(4):462-3 [9196447.001]
  • [Cites] Mol Med Today. 1995 Apr;1(1):26-30 [9415134.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41207 [16178631.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Mar;6(2):231-44 [16512782.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1181-91 [16778828.001]
  • [Cites] Nano Lett. 2006 Dec;6(12):2881-6 [17163724.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:257-88 [17439359.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-40 [18495291.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 19;374(2):181-6 [18621021.001]
  • [Cites] J Pathol. 2008 Nov;216(3):275-85 [18814189.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Nat Methods. 2009 Feb;6(2):139-41 [19137005.001]
  • [Cites] Biomaterials. 2009 May;30(15):2912-8 [19251316.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Trends Biotechnol. 2009 Jun;27(6):350-8 [19409634.001]
  • [Cites] Biosens Bioelectron. 2009 Aug 15;24(12):3657-62 [19540102.001]
  • [Cites] J Mol Histol. 2009 Aug;40(4):261-8 [19908148.001]
  • [Cites] ACS Nano. 2010 Jan 26;4(1):488-94 [20041634.001]
  • [Cites] N Engl J Med. 2010 Mar 11;362(10):875-85 [20220182.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • (PMID = 20565106.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108468; United States / NCI NIH HHS / CA / CA119338-01; United States / NCI NIH HHS / CA / U54CA119338; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / CA108468-01; United States / NCI NIH HHS / CA / R01 CA108468-01; United States / NCI NIH HHS / CA / R01CA108468; United States / NCI NIH HHS / CA / U54 CA119338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS220487; NLM/ PMC2914471
  •  go-up   go-down


45. Takano S, Sogawa K, Yoshitomi H, Shida T, Mogushi K, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Ishihara T, Tanaka H, Yokosuka O, Nomura F, Miyazaki M: Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer; 2010 Jul 13;103(2):223-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analysed the serum phosphoproteins that comprised cancer cellular signal pathways by comparing sera from PaCa patients and benign controls including healthy volunteers (HVs) and pancreatitis patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Pancreatic Neoplasms / diagnosis. Phosphoproteins / blood. Signal Transduction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1933-45 [16099937.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3360-4 [16585153.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1388-94 [18311901.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2841-9 [18413752.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2810-22 [18037960.001]
  • [Cites] J Theor Biol. 2008 Aug 7;253(3):616-22 [18513748.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):4164-72 [18642943.001]
  • [Cites] Anal Chem. 2009 Jan 1;81(1):94-104 [19117447.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] J Clin Chem Clin Biochem. 1987 May;25(5):337-42 [3612033.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3614-21 [15908672.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • (PMID = 20551957.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Phosphoproteins; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases
  • [Other-IDs] NLM/ PMC2906731
  •  go-up   go-down


46. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • By ROC analysis, the AGR2 ELISA achieved 67% sensitivity at 90% specificity in predicting PanIN3 juice samples from the benign disease controls.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


47. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ: Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem; 2008 Jan;54(1):44-52
Biospecimen Research Database. Biospecimen Research Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
  • METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Dis Markers. 2003-2004;19(4-5):185-95 [15258333.001]
  • [Cites] Clin Chem. 2004 Dec;50(12):2398-401 [15563493.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1525-8 [15951319.001]
  • [Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]
  • [Cites] Proteomics. 2006 Mar;6(5):1676-80 [16447157.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):771-2; author reply 772 [16595832.001]
  • [Cites] Proteomics. 2006 May;6(10):3189-98 [16586434.001]
  • [Cites] Clin Chem. 2006 Jul;52(7):1218-22 [16675505.001]
  • [Cites] Biometrics. 2006 Jun;62(2):589-97 [16918924.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2079-82 [16944917.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103 [17299447.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):645-56 [17303688.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):3-5 [18160722.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):6-7 [18160723.001]
  • (PMID = 17981926.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS371877; NLM/ PMC3354530
  •  go-up   go-down


48. Adley BP, Yang XJ: Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol; 2006 Feb;28(1):1-13
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
  • Since its discovery, AMACR has gained wide acceptance for use in the diagnosis of prostatic adenocarcinoma in conjunction with morphology and immunohistochemical staining for basal cell markers.
  • This review focuses on AMACR expression in prostate cancer and its morphologic variants, high grade prostatic intraepithelial neoplasia, adenosis and benign conditions of the prostate.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566275.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Number-of-references] 63
  •  go-up   go-down


49. Yang BL, Gu YF, Shao WJ, Chen HJ, Sun GD, Jin HY, Zhu X: Retrorectal tumors in adults: magnetic resonance imaging findings. World J Gastroenterol; 2010 Dec 14;16(46):5822-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Fourteen benign cystic lesions appeared hypointense on T1-weighted images, and hyperintense on T2-weighted images with regular peripheral rim.
  • There was a fistula between the mass and anus with an internal opening in mucinous adenocarcinomas arising from anal fistula.
  • CONCLUSION: MRI is a helpful technique to define the extent of the retrorectal tumor and its relationship to the surrounding structures, and also to demonstrate possible complications so as to choose the best surgical approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):731-2 [9294562.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1056-8 [9715165.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):251-4 [15967315.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Yonsei Med J. 2005 Aug 31;46(4):555-61 [16127782.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):498-500 [17680300.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2586-93 [18566821.001]
  • [Cites] Can J Surg. 2008 Dec;51(6):E115-6 [19057717.001]
  • [Cites] Am Surg. 2009 Mar;75(3):240-8 [19350861.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):705-14 [12023574.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Hum Pathol. 2002 May;33(5):456-8 [12094369.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):55-7 [12750956.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 21155003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3001973
  •  go-up   go-down


50. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy with histologic diagnosis was used as the gold standard for diagnosis.
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


51. Hsu A, Bray TM, Helferich WG, Doerge DR, Ho E: Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med (Maywood); 2010 Jan;235(1):90-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign prostate hyperplasia (BPH-1), LnCap and PC3 cells were treated with varying concentrations of soy extract, genistein or daidzein and analyzed for cell cycle alterations and induction of apoptosis.
  • No significant changes in cell cycle arrest or apoptosis were observed in non-cancerous BPH-1 cells treated with soy extract, suggesting that the effects of soy extract may be tumor cell specific.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2003;21(5):744-57 [14628433.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1328-31 [8443813.001]
  • [Cites] Lancet. 1993 Nov 13;342(8881):1209-10 [7901532.001]
  • [Cites] Mutagenesis. 1994 Mar;9(2):101-6 [8201941.001]
  • [Cites] Carcinogenesis. 1996 Jul;17(7):1451-7 [8706248.001]
  • [Cites] Proc Soc Exp Biol Med. 1998 Mar;217(3):310-6 [9492340.001]
  • [Cites] J Cell Biochem. 1998 Apr 1;69(1):44-54 [9513045.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1055-65 [9829717.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] Nutr Cancer. 1999;33(2):125-31 [10368806.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3486S-3492S [15570058.001]
  • [Cites] J Nutr. 2005 Jun;135(6):1400-6 [15930444.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):667-9 [15945102.001]
  • [Cites] J Agric Food Chem. 2005 Nov 2;53(22):8542-50 [16248551.001]
  • [Cites] BJU Int. 2005 Dec;96 Suppl 2:30-4 [16359436.001]
  • [Cites] J Nutr. 2006 Jan;136(1):75-82 [16365062.001]
  • [Cites] Prostate. 2006 Apr 1;66(5):557-66 [16372328.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45 [17337648.001]
  • [Cites] J Nutr. 2007 Apr;137(4):964-72 [17374662.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1773(6):903-11 [17490757.001]
  • [Cites] Nutr Cancer. 2007;57(2):184-93 [17571952.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):6-12 [17923857.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncol Rep. 2008 Apr;19(4):1061-6 [18357397.001]
  • [Cites] Oncogene. 2008 Oct 20;27(48):6252-75 [18931692.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53 [8382517.001]
  • [Cites] Nutr Cancer. 1999;35(2):167-74 [10693171.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):164-73 [10761703.001]
  • [Cites] Am J Clin Nutr. 2000 Jun;71(6 Suppl):1705S-7S; discussion 1708S-9S [10837323.001]
  • [Cites] Prostate. 2001 May 15;47(3):183-8 [11351347.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4188-97 [11464285.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3095S-108S [11694655.001]
  • [Cites] Prostate. 2002 May 1;51(2):133-40 [11948968.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2369-77 [12114442.001]
  • [Cites] J Nutr. 2002 Oct;132(10):3168-71 [12368413.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4702-9 [12879015.001]
  • [Cites] Toxicol Lett. 2004 Apr 15;150(1):43-56 [15068824.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):263-72 [15134504.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1649-57 [15131010.001]
  • [Cites] Urology. 2004 Sep;64(3):510-5 [15351581.001]
  • [Cites] Annu Rev Plant Biol. 2004;55:225-61 [15377220.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1389-95 [15492830.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Br J Nutr. 2004 Apr;91(4):513-31 [15035679.001]
  • (PMID = 20404023.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / CA107693; United States / NCI NIH HHS / CA / R01 CA107693; United States / NIA NIH HHS / AG / P01 AG024387; United States / NIA NIH HHS / AG / P01-AG024387; United States / NIEHS NIH HHS / ES / P30 ES000210
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / BAX protein, human; 0 / Isoflavones; 0 / NF-kappa B; 0 / Phytoestrogens; 0 / Plant Extracts; 0 / bcl-2-Associated X Protein; 1POG3SCN5T / genistin; 6287WC5J2L / daidzein; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS617415; NLM/ PMC4125131
  •  go-up   go-down


52. Almsherqi Z, Hyde S, Ramachandran M, Deng Y: Cubic membranes: a structure-based design for DNA uptake. J R Soc Interface; 2008 Sep 6;5(26):1023-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cubic membranes thus may offer a new, potentially benign medium for gene transfection.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):18997-9007 [7642560.001]
  • [Cites] FEBS Lett. 1995 Aug 1;369(1):13-7 [7641875.001]
  • [Cites] Curr Opin Struct Biol. 1997 Oct;7(5):661-8 [9345624.001]
  • [Cites] Biosci Rep. 1997 Dec;17(6):507-20 [9561295.001]
  • [Cites] Chemphyschem. 2004 Oct 18;5(10):1619-23 [15535566.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1335-9 [16287225.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 30;1746(3):349-63 [16440447.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):839-44 [16785319.001]
  • [Cites] J Agric Food Chem. 2007 Mar 7;55(5):1915-22 [17263546.001]
  • [Cites] Langmuir. 2007 Nov 20;23(24):12003-9 [17949111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12293-8 [10535915.001]
  • [Cites] J Struct Biol. 1999 Oct;127(3):231-9 [10544048.001]
  • [Cites] Nature. 2003 Mar 6;422(6927):37-44 [12621426.001]
  • [Cites] J Am Chem Soc. 2003 Jun 18;125(24):7188-9 [12797787.001]
  • [Cites] Mol Ther. 2003 Dec;8(6):957-63 [14664798.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Gene Ther. 1996 Nov;3(11):1010-7 [9044741.001]
  • (PMID = 18270148.001).
  • [ISSN] 1742-5689
  • [Journal-full-title] Journal of the Royal Society, Interface
  • [ISO-abbreviation] J R Soc Interface
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Phosphorothioate Oligonucleotides; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2607430
  •  go-up   go-down


53. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


54. Dey P: Basic principles and applications of fractal geometry in pathology: a review. Anal Quant Cytol Histol; 2005 Oct;27(5):284-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fractal geometry has been applied to measure the irregularities of nuclear and glandular margins to distinguish malignant lesions from benign ones, to measure the infiltrative margin of a malignant tumor, to assess tumor angiogenesis and to measure the distribution of collagen in tissue.
  • In the future, fractal geometry may help with the diagnosis, understanding of pathogenesis and management of lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447821.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


55. Kirillov VA, Stebenyaeva EE, Paplevka AA, Demidchik EP: Quantitative changes in thyroid lymphoid cells as a marker of malignancy. Anal Quant Cytol Histol; 2005 Apr;27(2):101-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These features formed the criteria for differentiation between malignant and benign disease.
  • The values for the diagnostic index for the groups with malignant and benign pathology differed significantly.
  • CONCLUSION: One can determine the presence of a malignant tumor in the thyroid gland from the diagnostic index value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913203.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikström P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One; 2010;5(12):e14175
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY/PRINCIPAL FINDINGS: Metabolomics was applied for the study of PCa bone metastases (n = 20) in comparison with corresponding normal bone (n = 14), and furthermore of malignant (n = 13) and benign (n = 17) prostate tissue and corresponding plasma samples obtained from patients with (n = 15) and without (n = 13) diagnosed metastases and from men with benign prostate disease (n = 30).
  • Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.
  • Immunohistochemical staining of PCa bone metastases showed intense staining of the low density lipoprotein receptor and variable levels of the scavenger receptor class B type 1 and 3-hydroxy-3-methylglutaryl-coenzyme reductase in tumor epithelial cells, indicating possibilities for influx and de novo synthesis of cholesterol.
  • [MeSH-minor] Biopsy. Bone and Bones / pathology. Computational Biology / methods. Gas Chromatography-Mass Spectrometry / methods. Humans. Immunohistochemistry / methods. Male. Neoplasm Metastasis. Prostatic Neoplasms / pathology. Sarcosine / metabolism. Tissue Distribution

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2001 Dec;10(6):507-13 [11916349.001]
  • [Cites] PLoS One. 2009;4(9):e7075 [19763266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):39-77 [14592533.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1150-60 [15130918.001]
  • [Cites] Prog Clin Biol Res. 1981;75A:279-324 [6175978.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Prostate. 1992;20(2):151-8 [1549552.001]
  • [Cites] Magn Reson Med. 1992 May;25(1):140-7 [1375702.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):149-57 [8429778.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1429-34 [9673351.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5635-42 [16131076.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):8086-94 [16351159.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1407-14 [16739992.001]
  • [Cites] Urology. 2006 Jun;67(6):1205-11 [16765180.001]
  • [Cites] Curr Treat Options Oncol. 2006 Sep;7(5):355-62 [16904052.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2265-77 [16455816.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] J Urol. 2007 Dec;178(6):2252-9 [17936845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7 [17971518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Pharmacol Sci. 2008 Apr;106(4):536-41 [18431036.001]
  • [Cites] Trends Endocrinol Metab. 2008 May-Jun;19(4):113-21 [18356074.001]
  • [Cites] J Urol. 2008 Jun;179(6):2422-6 [18433783.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Mol Cancer. 2008;7:72 [18799019.001]
  • [Cites] Cancer Biomark. 2008;4(4-5):263-76 [18957715.001]
  • [Cites] Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20 [18782595.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1259-66 [18704722.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):352-61 [19063642.001]
  • [Cites] Cancer Treat Rev. 2009 Feb;35(1):1-8 [18778896.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):1017-26 [19179610.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3058-67 [19544547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13 [19887582.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):781-7 [19526315.001]
  • [Cites] Endocr Relat Cancer. 2010 Dec;17(4):885-95 [20688881.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2227-31 [11956073.001]
  • (PMID = 21151972.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol; Z711V88R5F / Sarcosine
  • [Other-IDs] NLM/ PMC2997052
  •  go-up   go-down


57. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.
  • A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • (PMID = 20196536.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177
  •  go-up   go-down


58. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY: Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest; 2009 Jun;27(5):549-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
  • To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology.
  • Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1128-36 [16489065.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] JAMA. 2006 May 17;295(19):2234-8 [16705097.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3973-8 [16921049.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2317-21 [17119066.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):665-74; discussion 674 [16956712.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] J Urol. 2001 Jan;165(1):119-25 [11125379.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1815-26 [11696442.001]
  • [Cites] Urology. 2001 Jun;57(6):1033-7 [11377299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3376-85 [12177097.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1174-8 [12800218.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1100-9 [12801870.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] J Pathol. 2004 Feb;202(2):233-40 [14743506.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1633-8 [15073850.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 May 1;196(3):422-30 [15094313.001]
  • [Cites] Urologe A. 2004 May;43(5):573-9 [15029477.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3935-6 [15217922.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):125-35 [15247353.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):549-53 [8621277.001]
  • [Cites] Anal Biochem. 1998 Sep 10;262(2):185-92 [9750131.001]
  • [Cites] Clin Chim Acta. 2004 Dec;350(1-2):181-8 [15530476.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):103-15 [15657340.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] J Urol. 2005 Dec;174(6):2191-6 [16280762.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] J Urol. 2007 Aug;178(2):459-63; discussion 463 [17561132.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1679-86 [17601725.001]
  • [Cites] J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1 [18289596.001]
  • [Cites] J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1 [18423693.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64 [18692327.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S11-5 [17084157.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • (PMID = 19229700.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091956-080012; United States / NCI NIH HHS / CA / P50 CA091956; United States / NCI NIH HHS / CA / CA091956; United States / NCI NIH HHS / CA / P50 CA091956-080012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS99244; NLM/ PMC2693083
  •  go-up   go-down


59. Cho SD, Herzig DO, Douthit MA, Deveney KE: Treatment strategies and outcomes for rectal villous adenoma from a single-center experience. Arch Surg; 2008 Sep;143(9):866-70; discussion 871-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Retrospective review of patient and tumor characteristics, procedure, recurrence, and complications.
  • Mean tumor size was 3.0 cm (range, 0.5-11 cm) and the mean distance of the tumor from the anal verge was 4.9 cm (range, 0-10 cm).
  • Tumor size did not correlate with malignancy.
  • There were 4 (12.5%) benign recurrences, all after transanal excisions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794424.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Miragliotta V, Ipiña Z, Lefebvre-Lavoie J, Lussier JG, Theoret CL: Equine CTNNB1 and PECAM1 nucleotide structure and expression analyses in an experimental model of normal and pathological wound repair. BMC Physiol; 2008;8:1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specifically, wounds on horse limbs often develop exuberant granulation tissue which behaves clinically like a benign tumor and resembles the human keloid in that the evolving scar is trapped in the proliferative phase of repair, leading to fibrosis.

  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 1;164(1):452-62 [10605042.001]
  • [Cites] J Surg Res. 2007 Mar;138(1):141-50 [17109886.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1854-60 [11238129.001]
  • [Cites] Vet Surg. 2001 May-Jun;30(3):269-77 [11340559.001]
  • [Cites] J Dermatol Sci. 2001 Nov;27(3):170-7 [11641056.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C1181-90 [11940533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):200-3 [12110892.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Sep;283(3):C811-21 [12176738.001]
  • [Cites] Am J Vet Res. 2002 Nov;63(11):1564-70 [12428668.001]
  • [Cites] Mol Reprod Dev. 2003 Feb;64(2):152-65 [12506347.001]
  • [Cites] J Cell Biochem. 2003 Apr 1;88(5):1012-24 [12616538.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 28;303(1):212-8 [12646189.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):371-81 [12750905.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):72-8 [12866408.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Diabetes. 2004 Sep;53(9):2509-17 [15331568.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]
  • [Cites] Science. 1991 Nov 29;254(5036):1359-61 [1962194.001]
  • [Cites] J Cell Biol. 1992 Sep;118(6):1511-22 [1522121.001]
  • [Cites] Science. 1993 Dec 3;262(5139):1580-2 [8248808.001]
  • [Cites] Cell. 1994 Mar 11;76(5):789-91 [7907279.001]
  • [Cites] J Immunol. 1996 Feb 15;156(4):1515-24 [8568255.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):638-42 [8757136.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):5-9 [9884328.001]
  • [Cites] Dev Dyn. 1999 Jan;214(1):44-54 [9915575.001]
  • [Cites] FEBS Lett. 1999 Jan 15;442(2-3):178-82 [9928997.001]
  • [Cites] Equine Vet J. 1999 Jan;31(1):61-7 [9952331.001]
  • [Cites] Development. 1999 May;126(10):2285-98 [10207152.001]
  • [Cites] J Cell Sci. 1999 Sep;112 Pt 18:3005-14 [10462517.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):416-25 [15654359.001]
  • [Cites] N Z Vet J. 2005 Feb;53(1):69-76 [15731837.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1225-33 [15766557.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):59-69 [15972952.001]
  • [Cites] Physiol Genomics. 2005 Jul 14;22(2):157-70 [15870397.001]
  • [Cites] Biol Reprod. 2005 Aug;73(2):324-33 [15829623.001]
  • [Cites] Wound Repair Regen. 2005 Sep-Oct;13(5):520-9 [16176461.001]
  • [Cites] BMC Cell Biol. 2006;7:4 [16426441.001]
  • [Cites] Clin Sci (Lond). 2006 May;110(5):587-95 [16402918.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):314-24 [16816383.001]
  • [Cites] FASEB J. 2001 Feb;15(2):362-72 [11156952.001]
  • (PMID = 18237399.001).
  • [ISSN] 1472-6793
  • [Journal-full-title] BMC physiology
  • [ISO-abbreviation] BMC Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2268708
  •  go-up   go-down


61. Schrecengost JE, Tabbara S, Patterson J, Wick MR: Cutaneous mesenchymal hamartoma with mixed myogenous differentiation. J Cutan Pathol; 2006 Apr;33(4):327-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry showed positive staining for muscle-specific actin and desmin in the fascicular components of the lesion, and smooth muscle actin, desmin, and h-caldesmon positivity in a haphazard collection of muscle fibers in the deep dermis and anal submucosa.
  • They must be distinguished from a variety of other tumors, including juvenile rhabdomyoma, benign Triton tumor, and rhabdomyosarcoma.
  • [MeSH-major] Cell Differentiation. Dermis / pathology. Hamartoma / diagnosis. Mesoderm / pathology. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630187.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


62. Zhang S, Gao F, Chen LS, Tang ZJ, Liang JL, Wu Q: [Clinical analysis of anorectal malignant melanoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jul;8(4):309-11
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The onset of symptom was hematochezia, then anus prolapses.
  • 94.7% of patients had AMM within 5 cm from anus margin; the average tumor size was (3.3+/- 2.1) cm.
  • More than a half (54.5%) of the tumor was movable, 19.1% smooth surfaced, 6.6% soft textured.
  • Half of the patients were misdiagnosed,and over 50% of patients were misdiagnosed as benign disease.
  • Mile's operation was performed in most of patients (63%), while anal resection was performed in 30% of the patients.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167248.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Cardillo MR, Gentile V, Ceccariello A, Giacomelli L, Messinetti S, Di Silverio F: Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer? BMC Cancer; 2005;5:111
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Circulating cells were identified by reverse transcription-polymerase chain reaction (RT-PCR) to detect p503S, p504S and p510S mRNA in peripheral blood (PB) from 11 patients with treated prostatic carcinoma (CaP), 11 with newly-diagnosed untreated CaP and 20 with benign prostatic hyperplasia (BPH) (controls).
  • [MeSH-major] Biomarkers, Tumor. Gene Expression Regulation, Neoplastic. Membrane Proteins / blood. Multidrug Resistance-Associated Proteins / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / blood

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):834-43 [15173267.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):641-3 [15389976.001]
  • [Cites] Scand J Clin Lab Invest. 2004;64(7):687-89 [15513326.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(18):6133-7 [2994062.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Anticancer Res. 1987 Sep-Oct;7(5B):927-35 [2449118.001]
  • [Cites] Mol Pharmacol. 1997 Apr;51(4):576-82 [9106621.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 16;1478(1):159-63 [10719184.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6485-8 [12438241.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):305-8 [12680228.001]
  • [Cites] Gene. 2004 Feb 18;327(1):89-98 [14960364.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):813-5 [15173257.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):267-80 [9531564.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2741-7 [9661885.001]
  • [Cites] J Urol. 2004 Sep;172(3):1130-3 [15311056.001]
  • (PMID = 16143040.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCC4 protein, human; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Membrane Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / TSPAN1 protein, human; 0 / Tetraspanins; 63231-63-0 / RNA; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC1236915
  •  go-up   go-down


64. Balducci C, Lilli C, Stabellini G, Marinucci L, Giustozzi G, Becchetti A, Cagini L, Locci P: Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene. BMC Cancer; 2005 Mar 1;5:22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoid tumour is a benign, non metastasising neoplasm characterised by an elevated deposition of organic macromolecules in the extracellular matrix (ECM).
  • The MMPs and their natural inhibitors (TIMPs) have been implicated in tumour growth, invasion and metastasis.
  • In this study we provide evidence that the in vitro cultured cell line from desmoid tumour accumulates more collagen fibres in the ECM than healthy fibroblasts.
  • [MeSH-minor] Antineoplastic Agents, Hormonal / pharmacology. Cell Line, Tumor. Collagenases / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Procollagen / analysis. Tissue Inhibitor of Metalloproteinases / metabolism. Tumor Cells, Cultured. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Interferon Cytokine Res. 2001 Nov;21(11):961-70 [11747628.001]
  • [Cites] Mol Cell Biochem. 1999 Apr;194(1-2):99-108 [10391129.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):824-32 [11948458.001]
  • [Cites] J Periodontol. 2002 Nov;73(11):1313-22 [12479636.001]
  • [Cites] Biol Reprod. 2003 Apr;68(4):1276-81 [12606436.001]
  • [Cites] Biochem J. 2003 Sep 15;374(Pt 3):739-45 [12755684.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40364-72 [12904305.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):49-55 [14550952.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Jul 1;96(1):220-4 [495986.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1014-8 [1385717.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(2):197-250 [8435466.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 11;261(3):904-10 [10441523.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Anal Biochem. 1998 Jan 15;255(2):211-6 [9451506.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):5872-6 [7890717.001]
  • [Cites] Aust N Z J Surg. 1996 Jul;66(7):457-63 [8678875.001]
  • [Cites] Am J Hum Genet. 1996 Dec;59(6):1193-201 [8940264.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Cytokine. 1998 May;10(5):353-60 [9619373.001]
  • [Cites] Pathol Int. 1998 Aug;48(8):603-10 [9736407.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):602-8 [9818170.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):667-71 [9818179.001]
  • [Cites] Gut. 1998 Dec;43(6):791-7 [9824606.001]
  • [Cites] Ann Med. 1999 Feb;31(1):34-45 [10219712.001]
  • [Cites] Int J Dev Biol. 1999 Mar;43(2):157-65 [10235392.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 1):L814-24 [10330038.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):866-72; discussion 872-3 [10363901.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Curr Med Chem. 2001 Mar;8(4):425-74 [11172697.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):507-15 [11477554.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2396-404 [11489818.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):17-25 [11773278.001]
  • (PMID = 15740610.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Matrix Metalloproteinase Inhibitors; 0 / Procollagen; 0 / Tissue Inhibitor of Metalloproteinases; 7NFE54O27T / Toremifene; 9007-34-5 / Collagen; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC555538
  •  go-up   go-down


65. Cataldo PA, O'Brien S, Osler T: Transanal endoscopic microsurgery: a prospective evaluation of functional results. Dis Colon Rectum; 2005 Jul;48(7):1366-71
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Local excision is a commonly used technique for many benign and selected malignant rectal lesions.
  • Fourteen patients had malignant lesions and 27 had benign lesions.
  • Two patients required abdominoperineal resection based on postoperative diagnosis.
  • Average distance from the anal verge to the proximal tumor margin was 11.4 cm and mean tumor size was 8.75 cm.
  • [MeSH-minor] Anal Canal. Fecal Incontinence / etiology. Fecal Incontinence / physiopathology. Female. Humans. Length of Stay / statistics & numerical data. Male. Postoperative Complications. Prospective Studies. Quality of Life. Statistics, Nonparametric. Surveys and Questionnaires. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933798.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Zheng Y, Englander S, Baloch S, Zacharaki EI, Fan Y, Schnall MD, Shen D: STEP: spatiotemporal enhancement pattern for MR-based breast tumor diagnosis. Med Phys; 2009 Jul;36(7):3192-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STEP: spatiotemporal enhancement pattern for MR-based breast tumor diagnosis.
  • By viewing serial contrast-enhanced MR images as a single spatiotemporal image, they formulate the STEP as a combination of (1) dynamic enhancement and architectural features of a tumor, and (2) the spatial variations of pixelwise temporal enhancements.
  • Although the latter has been widely used by radiologists for diagnostic purposes, it has rarely been employed for computer-aided diagnosis.
  • The STEP features are assessed through their diagnostic performance for differentiating between benign and malignant tumors using a linear classifier (along with a simple ranking-based feature selection) in a leave-one-out cross-validation setting.
  • [MeSH-major] Breast Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol. 2003 Jul;44(4):379-86 [12846687.001]
  • [Cites] IEEE Trans Med Imaging. 2008 May;27(5):688-96 [18450541.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2001 May;9(2):295-302, vi [11493420.001]
  • [Cites] J Magn Reson Imaging. 1999 Dec;10(6):982-90 [10581516.001]
  • [Cites] Med Phys. 2004 May;31(5):1076-82 [15191295.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Med Phys. 1998 Sep;25(9):1647-54 [9775369.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):207-24 [9873907.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Acad Radiol. 2004 Dec;11(12):1344-54 [15596372.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Radiology. 2006 Jan;238(1):42-53 [16373758.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] Med Phys. 2006 Aug;33(8):2878-87 [16964864.001]
  • [Cites] IEEE Trans Med Imaging. 2006 Dec;25(12):1627-36 [17167997.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):393-401 [18044593.001]
  • [Cites] NMR Biomed. 2002 Apr;15(2):154-63 [11870911.001]
  • (PMID = 19673218.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA140841; United States / NCI NIH HHS / CA / 1R21CA140841
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2852449
  •  go-up   go-down


67. Poola I, Abraham J, Marshalleck JJ, Yue Q, Fu SW, Viswanath L, Sharma N, Hill R, Dewitty RL, Bonney G: Molecular constitution of breast but not other reproductive tissues is rich in growth promoting molecules: a possible link to highest incidence of tumor growths. FEBS Lett; 2009 Sep 17;583(18):3069-75
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular constitution of breast but not other reproductive tissues is rich in growth promoting molecules: a possible link to highest incidence of tumor growths.
  • In the current study we tested if highest incidence of benign as well as cancer growths in breast tissue is due to constitutive molecular composition of this tissue.
  • We present data to demonstrate that breast tissues constitutively have very highly elevated levels of several growth promoting molecules and diminished levels of inhibitory molecules which may, in part, contribute for highest incidence of tumor growths in this tissue.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 2002 Oct;82(2-3):169-79 [12477483.001]
  • [Cites] Anal Biochem. 2003 Mar 15;314(2):217-26 [12654308.001]
  • [Cites] Endocrine. 2003 Nov;22(2):101-12 [14665713.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7579-85 [16243834.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8036-41 [16299233.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4773-83 [16899629.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1274-80 [18281563.001]
  • [Cites] Nat Med. 2005 May;11(5):481-3 [15864312.001]
  • (PMID = 19698714.001).
  • [ISSN] 1873-3468
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120365-02; United States / NCI NIH HHS / CA / R21 CA120365; United States / NCI NIH HHS / CA / R21 CA120365-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins
  • [Other-IDs] NLM/ NIHMS141649; NLM/ PMC2752361
  •  go-up   go-down


68. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Iqbal J, Liu T, Mapow B, Swami VK, Hou JS: Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies. Anal Quant Cytol Histol; 2010 Jun;32(3):161-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies.
  • OBJECTIVE: To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions.
  • The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM.
  • RESULTS: The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%).
  • In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases.
  • CONCLUSION: FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management.
  • In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701070.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Zubakov D, Stupar Z, Kovacs G: Differential expression of a new isoform of DLG2 in renal oncocytoma. BMC Cancer; 2006;6:106
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Renal oncocytoma, a benign tumour of the kidney, may pose a differential diagnostic problem due to overlapping phenotype with chromophobe renal cell carcinoma or other types of renal cell tumours.
  • Therefore, identification of molecular markers would be of great value for molecular diagnostics of this tumour type.
  • Subsequently, we used RACE and Northern blot hybridization to characterize the potential candidates for molecular diagnosis.
  • The new isoform is specifically upregulated in renal oncocytoma, whereas the known DLG2 gene is downregulated in this type of kidney tumour.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Guanylate Kinase / genetics. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / genetics. Diagnosis, Differential. Down-Regulation. Genetic Markers. Humans. Nucleic Acid Amplification Techniques. Oligonucleotide Array Sequence Analysis. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2005 Jan;36(1):22-8 [15712178.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):796-803 [10361516.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jul 15;160(2):120-5 [15993267.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):938-46 [16133362.001]
  • [Cites] Histopathology. 2000 Sep;37(3):264-8 [10971703.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):957-60 [11861363.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] Int J Dev Biol. 2002;46(4):511-8 [12141438.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Histopathology. 2004 Jun;44(6):542-6 [15186268.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Histopathology. 1993 Jan;22(1):1-8 [8436337.001]
  • [Cites] Neuron. 1996 Jul;17(1):103-13 [8755482.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2081-8 [8952540.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):419-24 [9537468.001]
  • [Cites] J Pathol. 1998 Jan;184(1):58-62 [9582528.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):262-8 [15791570.001]
  • (PMID = 16640776.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Protein Isoforms; 0 / Tumor Suppressor Proteins; EC 2.7.4.8 / DLG2 protein, human; EC 2.7.4.8 / Guanylate Kinase
  • [Other-IDs] NLM/ PMC1524971
  •  go-up   go-down


71. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


72. Xi Z, LinLin M, Ye T: Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal; 2009;23(6):357-61
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 102 patients with TCC, 60 with benign urinary diseases, and 60 healthy controls were included in this study.
  • RESULTS: The HE4 level was significantly increased in patients with TCC compared to patients with benign urinary diseases patients (P<0.01) and healthy controls (P<0.01), and the level of HE4 in patients with superficial TCC (Tis Ta T1) was significantly higher than that of the benign urogenital group (P<0.05)and healthy controls (P<0.05).
  • There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (P>0.05).
  • The HE4 level was also different between patients with a single tumor versus patients with multiple tumors.
  • CONCLUSIONS: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / blood. Epididymal Secretory Proteins / metabolism. Urologic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927341.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


73. Zhu X, Ma LL, Ye T: Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance. J Clin Lab Anal; 2009;23(4):197-201
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the expressions of CD4(+)CD25(high)CD127(low/-) regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4(+) T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation.
  • There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05).
  • The resection of tumor can decrease the proportion of Treg in peripheral blood.
  • [MeSH-major] Antigens, CD / immunology. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / immunology. T-Lymphocytes, Regulatory / immunology. Urologic Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623656.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Biomarkers, Tumor; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukin-7 Receptor alpha Subunit
  •  go-up   go-down


74. Satsuka A, Sakai H: [Life cycle of HPV governed by the differentiation program of epithelial cell]. Uirusu; 2008 Dec;58(2):165-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillomavirus is a pathogenic virus that induces benign tumor at the infected lesion, and its association with malignant tumor was first identified by R.
  • Because of its clinical importance, the study on HPV has been focused on the oncogenic properties, and the results of which had great impacts on the researches of the tumor suppressors, such as p53 and pRb, and "ubiquiitn-proteasome" pathway.
  • [MeSH-minor] Animals. Gene Expression Regulation, Viral. Gene Silencing. Genes, Tumor Suppressor. Genome, Viral. Humans. Open Reading Frames / genetics. Virus Replication / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374194.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 33
  •  go-up   go-down


75. Bearzi I, Mandolesi A, Arduini F, Costagliola A, Ranaldi R: Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. Anal Quant Cytol Histol; 2006 Jun;28(3):137-47
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors.
  • RESULTS: Most of the GISTs had a benign behavior.
  • CONCLUSION: Mitotic activity is important in predicting the outcome of patients with high risk GIST who present at diagnosis without dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786723.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


76. Sharif AW, Williams HR, Lampejo T, Khan SA, Bansi DS, Westaby D, Thillainayagam AV, Thomas HC, Cox IJ, Taylor-Robinson SD: Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB (Oxford); 2010 Aug;12(6):396-402
Hazardous Substances Data Bank. GLYCINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to compare the chemical composition of bile from patients with CCA with that of bile from patients with benign biliary disease.
  • METHODS: Magnetic resonance spectra were acquired from the bile of five CCA patients and compared with MRS of control bile from patients with benign biliary disease (seven with gallstones, eight with sphincter of Oddi dysfunction [SOD], five with primary sclerosing cholangitis [PSC]).
  • RESULTS: Univariate analysis showed that levels of glycine-conjugated bile acids were significantly increased in patients with CCA, compared with the benign disease groups (P= 0.002).
  • [MeSH-major] Bile / metabolism. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic / metabolism. Biomarkers, Tumor / metabolism. Cholangiocarcinoma / metabolism. Magnetic Resonance Spectroscopy. Metabolomics / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] MAGMA. 2009 Oct;22(5):267-75 [19390887.001]
  • [Cites] Gut. 2001 Jun;48(6):816-20 [11358902.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):985-93 [11910351.001]
  • [Cites] J Hepatol. 2002 Dec;37(6):806-13 [12445422.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1439-44 [12447357.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1464-9 [15307861.001]
  • [Cites] Br J Hosp Med. 1988 Sep;40(3):165 [3219460.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1237-45 [7977654.001]
  • [Cites] Cell. 1996 Nov 1;87(3):507-17 [8898203.001]
  • [Cites] NMR Biomed. 1998 Nov;11(7):370-9 [9859943.001]
  • [Cites] Gastroenterology. 1999 Jan;116(1):179-86 [9869616.001]
  • [Cites] J Lipid Res. 1999 Oct;40(10):1920-4 [10508212.001]
  • [Cites] Nat Rev Microbiol. 2005 May;3(5):431-8 [15821725.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Jul;17(7):733-8 [15947550.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Free Radic Biol Med. 2005 Dec 1;39(11):1418-27 [16274877.001]
  • [Cites] Aliment Pharmacol Ther. 2006 May 1;23(9):1287-96 [16629933.001]
  • [Cites] World J Gastroenterol. 2006 Aug 14;12(30):4773-83 [16937457.001]
  • [Cites] Lipids. 2006 Jun;41(6):591-603 [16981437.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):77-98 [17295178.001]
  • [Cites] Acta Radiol. 2008 Oct;49(8):855-62 [18608012.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7562-70 [18767870.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1435-44 [19491857.001]
  • [Cites] NMR Biomed. 2009 Jun;22(5):471-9 [19067402.001]
  • [Cites] World J Gastroenterol. 2009 Jul 21;15(27):3329-40 [19610133.001]
  • [Cites] Liver. 1999 Dec;19(6):501-8 [10661684.001]
  • (PMID = 20662790.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Phosphatidylcholines; TE7660XO1C / Glycine
  • [Other-IDs] NLM/ PMC3028580
  •  go-up   go-down


77. True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, Ellis WJ, Liebeskind ES, Liu AY: CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol; 2010 Oct;23(10):1346-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry showed that in all carcinomas, regardless of Gleason grade, a layer of CD90-positive stromal fibroblastic cells, ∼5 to 10 cells deep, was localized to tumor glands.
  • In contrast, a no more than 1-cell wide girth of CD90-positive stromal cells was found around benign glands.
  • There is increasing evidence that cancer-associated stroma has a function in both tumor progression and carcinogenesis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Tissue Res. 1999 Nov;298(2):307-15 [10571119.001]
  • [Cites] BMC Cancer. 2009;9:452 [20021671.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):405-12 [11232032.001]
  • [Cites] Proteomics. 2001 Aug;1(8):1010-21 [11683502.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):37-43 [11786396.001]
  • [Cites] Eur J Immunol. 2002 Feb;32(2):477-85 [11813166.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2912-23 [12231536.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):207-11 [12469170.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):506-21 [12492493.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):660-6 [12754519.001]
  • [Cites] Mol Cell Proteomics. 2003 Jul;2(7):426-7 [12832456.001]
  • [Cites] Mol Cell Proteomics. 2003 Jul;2(7):428-42 [12832459.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1291-300 [14507638.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):659-69 [15277239.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1543-56 [15509525.001]
  • [Cites] Biochem J. 1983 Feb 1;209(2):331-6 [6847620.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(19):6657-61 [2864690.001]
  • [Cites] Clin Immunol Immunopathol. 1995 Oct;77(1):42-51 [7554483.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10705-10 [9380699.001]
  • [Cites] Int J Oncol. 1998 Jul;13(1):35-47 [9625801.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92(4):221-36 [15663986.001]
  • [Cites] BMC Genomics. 2006;7:92 [16638148.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):64-71 [17030953.001]
  • [Cites] Nat Protoc. 2007;2(2):334-9 [17406594.001]
  • [Cites] BMC Cancer. 2009;9:317 [19737398.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):303-12 [10951495.001]
  • (PMID = 20562849.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR018522-07; United States / NCRR NIH HHS / RR / P41 RR018522; United States / NCI NIH HHS / CA / P50 CA097186; United States / NCI NIH HHS / CA / P01 CA085859; United States / NCI NIH HHS / CA / CA111244; United States / NCRR NIH HHS / RR / RR018522; None / None / / P41 RR018522-07; United States / NCI NIH HHS / CA / CA85859; United States / NCI NIH HHS / CA / U01 CA111244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Thy-1; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS203764; NLM/ PMC2948633
  •  go-up   go-down


78. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


79. Algaba F, Mikuz G, Boccon-Gibod L, Trias I, Arce Y, Montironi R, Egevad L, Scarpelli M, Lopez-Beltran A: Pseudoneoplastic lesions of the testis and paratesticular structures. Virchows Arch; 2007 Dec;451(6):987-97
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudotumors or tumor-like proliferations (non-neoplastic masses) and benign mimickers (non-neoplastic cellular proliferations) are rare in the testis and paratesticular structures.
  • The purpose of this paper is to present an overview of the pseudoneoplasic entities arising in the testis and paratesticular structures; emphasis is placed on how the practicing pathologist may distinguish benign mimickers and pseudotumors from true neoplasia.
  • These lesions can be classified as macroscopic or microscopic mimickers of neoplasia.
  • [MeSH-minor] Choristoma / diagnosis. Cysts / diagnosis. Diagnosis, Differential. Epididymitis / diagnosis. Humans. Male. Orchitis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1998 Feb;81(2):282-9 [9488073.001]
  • [Cites] Br J Urol. 1998 May;81(5):777 [9634068.001]
  • [Cites] Prog Urol. 1998 Jun;8(3):410-2 [9689677.001]
  • [Cites] J Urol. 1998 Nov;160(5):1838-41 [9783971.001]
  • [Cites] Am J Pathol. 1962 May;40:587-98 [13883088.001]
  • [Cites] Br J Urol. 1964 Jun;36:SUPPL:1-11 [14184707.001]
  • [Cites] Arch Androl. 2005 Sep-Oct;51(5):407-11 [16087569.001]
  • [Cites] J Ultrasound Med. 2005 Oct;24(10):1403-9; quiz 1410-1 [16179625.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):768-71 [16012849.001]
  • [Cites] Urol Oncol. 2006 Jan-Feb;24(1):36-9 [16414491.001]
  • [Cites] Int J Urol. 2006 Jan;13(1):95-7 [16448444.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):325-7 [16505287.001]
  • [Cites] Int J Urol. 2006 Feb;13(2):186-8 [16563149.001]
  • [Cites] Int Surg. 2006 May-Jun;91(3):125-8 [16845852.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Aug;28(4):181-7 [16927637.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):373-5 [16868781.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5668-72 [17020968.001]
  • [Cites] Arch Pathol Lab Med. 1996 Oct;120(10):959-66 [12046609.001]
  • [Cites] Transplant Proc. 2002 Sep;34(6):2141-2 [12270345.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1222-5 [12296764.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):215-40 [12533657.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):741-52 [12792886.001]
  • [Cites] J Urol. 2003 Jul;170(1):187-8 [12796682.001]
  • [Cites] Urology. 2003 Aug;62(2):352 [12893362.001]
  • [Cites] Urology. 2003 Sep;62(3):551 [12946770.001]
  • [Cites] Pathol Int. 2003 Dec;53(12):897-900 [14629758.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):799 [14713819.001]
  • [Cites] Am J Med Sci. 1995 Jan;309(1):63-5 [7825657.001]
  • [Cites] Br J Urol. 1995 Feb;75(2):255-7 [7850344.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1121-3 [7876390.001]
  • [Cites] Isr J Med Sci. 1995 Apr;31(4):235-6 [7721563.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):403-7 [7572789.001]
  • [Cites] Urol Int. 1995;55(4):222-5 [8588271.001]
  • [Cites] Eur J Radiol. 1999 Sep;31(3):201-3 [10566522.001]
  • [Cites] Urology. 1999 Aug;54(2):366 [10754657.001]
  • [Cites] Medicine (Baltimore). 2000 Nov;79(6):349-59 [11144033.001]
  • [Cites] Cutis. 2000 Dec;66(6):435-8 [11138361.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] Spinal Cord. 2000 Dec;38(12):769-72 [11175379.001]
  • [Cites] Radiology. 2001 Jul;220(1):70-5 [11425975.001]
  • [Cites] Rheumatol Int. 2001 Jul;20(5):215-6 [11518043.001]
  • [Cites] Radiographics. 2002 Jan-Feb;22(1):189-216 [11796908.001]
  • [Cites] Urology. 2002 Mar;59(3):445 [11880098.001]
  • [Cites] Clin Dysmorphol. 2002 Apr;11(2):87-90 [12002154.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):e60-2 [15043474.001]
  • [Cites] J Clin Pathol. 1980 Jul;33(7):670-8 [7430373.001]
  • [Cites] Boll Soc Ital Biol Sper. 1980 Oct 30;56(20):2110-5 [6109541.001]
  • [Cites] J Clin Ultrasound. 1982 Sep;10(7):353-5 [6815240.001]
  • [Cites] J Urol. 1983 Feb;129(2):380-1 [6834514.001]
  • [Cites] J Urol. 1983 Mar;129(3):610-2 [6834559.001]
  • [Cites] J Ultrasound Med. 1983 Feb;2(2):93-4 [6842663.001]
  • [Cites] Ann Dermatol Venereol. 1984;111(2):169-71 [6721363.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):579-83 [6547323.001]
  • [Cites] Am J Clin Pathol. 1984 Dec;82(6):710-3 [6507383.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1607-11 [3978555.001]
  • [Cites] Am J Clin Pathol. 1985 Apr;83(4):426-30 [3984936.001]
  • [Cites] J Urol. 1985 Dec;134(6):1211 [3903224.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jan;110(1):61-4 [3753572.001]
  • [Cites] Eur J Pediatr. 1985 Nov;144(4):316-23 [4076247.001]
  • [Cites] J Pediatr Surg. 1996 Mar;31(3):435-6 [8708920.001]
  • [Cites] Histopathology. 1996 Jan;28(1):77-80 [8838125.001]
  • [Cites] Urol Int. 1996;56(3):200-3 [8860745.001]
  • [Cites] Eur Urol. 1997;32(2):253-5 [9286662.001]
  • [Cites] Urology. 2004 Jan;63(1):176-7 [14751385.001]
  • [Cites] Can J Urol. 2004 Feb;11(1):2133-5 [15003152.001]
  • [Cites] Am J Surg Pathol. 1986 Jan;10(1):34-47 [3953932.001]
  • [Cites] Am J Trop Med Hyg. 1986 Jul;35(4):791-2 [3089039.001]
  • [Cites] Histopathology. 1986 Jul;10(7):741-8 [3527934.001]
  • [Cites] Appl Pathol. 1985;3(3):123-8 [3842073.001]
  • [Cites] J Urol. 1986 Dec;136(6):1219-20 [3773094.001]
  • [Cites] Eur Urol. 1986;12(5):362-3 [3780807.001]
  • [Cites] Eur Urol. 1987;13(5):327-30 [3678304.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1227-31 [2890567.001]
  • [Cites] Urology. 1988 Mar;31(3):245-6 [3347975.001]
  • [Cites] J Urol. 1988 Apr;139(4):798-9 [3352047.001]
  • [Cites] J Clin Pathol. 1988 Apr;41(4):419-23 [3366928.001]
  • [Cites] Radiology. 1988 Jul;168(1):19-23 [3289090.001]
  • [Cites] AJR Am J Roentgenol. 1988 Dec;151(6):1253 [2847517.001]
  • [Cites] Urology. 1989 Aug;34(2):102-4 [2669306.001]
  • [Cites] J Urol. 1990 May;143(5):1012-4 [2184251.001]
  • [Cites] Hum Pathol. 1990 Aug;21(8):866-8 [2387579.001]
  • [Cites] Pathol Annu. 1990;25 Pt 2:51-108 [2202966.001]
  • [Cites] Hum Pathol. 1990 Oct;21(10):1080-2 [2210732.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):66-74 [1702268.001]
  • [Cites] Am J Surg Pathol. 1991 Apr;15(4):350-7 [2006714.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(2):126-44 [2032766.001]
  • [Cites] Urol Radiol. 1991;13(2):129-32 [1897071.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):430-1 [1933169.001]
  • [Cites] Histopathology. 1991 Nov;19(5):468-70 [1757086.001]
  • [Cites] J Clin Ultrasound. 1992 Jan;20(1):51-8 [1309544.001]
  • [Cites] Arch Pathol Lab Med. 1992 Mar;116(3):277-80 [1536613.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):448-54 [1599023.001]
  • [Cites] J Urol. 1993 Jan;149(1):134-6 [8417196.001]
  • [Cites] Urol Radiol. 1992;14(3):205-10 [1290214.001]
  • [Cites] Actas Urol Esp. 1993 Jan;17(1):53-6 [8452084.001]
  • [Cites] Br J Urol. 1993 Aug;72(2):249 [8402034.001]
  • [Cites] Br J Urol. 1993 Oct;72(4):515-6 [8261316.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):477-8 [8015096.001]
  • [Cites] J Urol. 1994 Dec;152(6 Pt 1):2101-3 [7966688.001]
  • [Cites] Pediatr Radiol. 2004 May;34(5):421-3 [14685788.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):911-4 [15270607.001]
  • [Cites] Int J Urol. 2004 Aug;11(8):683-5 [15285765.001]
  • [Cites] Arch Pathol. 1968 Oct;86(4):438-41 [5698046.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1973 Sep 4;360(3):223-34 [4201287.001]
  • [Cites] Cancer. 1975 Jan;35(1):165-75 [1109769.001]
  • [Cites] N Engl J Med. 1977 Dec 29;297(26):1413-9 [200843.001]
  • [Cites] Arch Surg. 1978 Jul;113(7):814-6 [678090.001]
  • [Cites] Acta Anat (Basel). 1979;105(2):188-97 [532547.001]
  • [Cites] Histopathology. 1997 Oct;31(4):387-8 [9363460.001]
  • (PMID = 17805564.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 110
  • [Other-IDs] NLM/ PMC2082069
  •  go-up   go-down


80. Suzuki H, Furukawa K, Kan H, Tsuruta H, Matsumoto S, Akiya Y, Shinji S, Tajiri T: The role of transanal endoscopic microsurgery for rectal tumors. J Nippon Med Sch; 2005 Oct;72(5):278-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal endoscopic microsurgery (TEM) is both an effective treatment for benign rectal tumors and early cancers, and a diagnostic tool for determining tumor depth, or for residual tumors of post endoscopic mucosal resection.
  • The operations were performed by a single surgeon, and the indications were mainly limited to a) benign tumors for which endoscopic resection was difficult, b) early cancers that had invaded the submucosa within 500 microm of the muscularis mucosae, c) submucosal tumors, i.e., gastrointestinal stromal tumor, carcinoid tumors, d) local excision for diagnosis, and e) palliative resection for high-risk cases.
  • Anesthesia, operation time, sizes of the tumor and of resected specimens, postoperative complications, length of hospitalization, pathological results, and postoperative recurrence rate were reviewed.
  • RESULTS: The mean age of patients was 61.9 years, and the cases included 14 rectal cancers, 7 adenomas, 1 gastrointestinal stromal tumor, and 3 rectal carcinoid tumors.
  • In one case, the tumor had infiltrated the proper muscle layer, as shown by intraoperative frozen sectioning, which necessitated abdominoperineal resection.
  • Although TEM requires technical skill and accurate preoperative diagnosis, the procedure is safe, facilitates accurate diagnosis of tumor depth, and limits the need for additional surgery.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247227.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Ramirez JM, Aguilella V, Gracia JA, Ortego J, Escudero P, Valencia J, Esco R, Martinez M: Local full-thickness excision as first line treatment for sessile rectal adenomas: long-term results. Ann Surg; 2009 Feb;249(2):225-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The selection criteria were benign sessile adenomas below the peritoneal reflection.
  • In the study period, 173 patients were operated on for an apparently benign rectal adenoma.
  • The mean distance of lower tumor was 7.6 cm (range, 1-18 cm), and the mean distance to upper edge was 11 cm (2-20 cm).
  • No statistical differences were found when comparing the histologic findings by tumor size, distance to the anal verge, or location.In 10 (5.8%) cases, the dissection was considered uncompleted because of a normal mucosa margin smaller than 1 mm.
  • CONCLUSIONS: In conclusion, a significant number of adenomas that we assumed preoperatively to be benign were already carcinomas and we were unable to find any reliable predictor to identify them.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Proctoscopy. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212174.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Plathow C, Schoebinger M, Herth F, Tuengerthal S, Meinzer HP, Kauczor HU: Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results. Korean J Radiol; 2009 Nov-Dec;10(6):559-67
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients with NSCLC showed a local lack of lung motion in the area of the tumor.
  • In the patients with MPM, there was global diminished motion of the tumor bearing hemithorax, which improved significantly after chemotherapy (CHT) (assessed by the 2D- and 3D-techniques) (p < 0.01).
  • Local and global parenchymal pathologies can be precisely located and might be a new tool used to quantify even slight changes in lung motion (e.g. in therapy monitoring, follow-up studies or even benign lung diseases).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):467-74 [11241824.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):631-5 [17685425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):335-41 [12738306.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):542-7 [14509953.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):968-78 [14575827.001]
  • [Cites] Acad Radiol. 2003 Oct;10(10):1147-52 [14587632.001]
  • [Cites] Invest Radiol. 2004 Apr;39(4):202-9 [15021323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):952-9 [15234028.001]
  • [Cites] Eur Radiol. 2004 Aug;14(8):1392-9 [15127220.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):335-41 [15337573.001]
  • [Cites] Am Rev Respir Dis. 1987 Oct;136(4):867-71 [3662240.001]
  • [Cites] Radiology. 1989 Jun;171(3):841-5 [2717762.001]
  • [Cites] Clin Chest Med. 1990 Sep;11(3):405-16 [2205439.001]
  • [Cites] J Magn Reson Imaging. 1999 Oct;10(4):510-20 [10508317.001]
  • [Cites] Radiother Oncol. 2004 Dec;73(3):349-54 [15588881.001]
  • [Cites] Invest Radiol. 2005 Jan;40(1):40-8 [15597019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):594-607 [15667982.001]
  • [Cites] Invest Radiol. 2005 Mar;40(3):173-9 [15714092.001]
  • [Cites] Med Image Anal. 2005 Dec;9(6):594-604 [15896995.001]
  • [Cites] Invest Radiol. 2006 May;41(5):443-8 [16625107.001]
  • [Cites] Radiology. 2006 Aug;240(2):537-45 [16801367.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1942-50 [16628438.001]
  • [Cites] Methods Inf Med. 2007;46(3):275-81 [17492112.001]
  • [Cites] Inf Process Med Imaging. 2007;20:1-12 [17633684.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):131-8 [12601277.001]
  • (PMID = 19885311.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2770821
  • [Keywords] NOTNLM ; Biomechanics / Dynamic MRI / Intraparenchymal lung motion / Pleural mesothelioma / Tumor
  •  go-up   go-down


83. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address: